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/~A STUDY OF  THE EVOLUTION 
OF  CONCENTRATION 
IN THE DANISH 
PHARMACEUTICAL  INDUSTRY  .,---PREFACE 
The  present volume  is part of a  series of sectoral studies on  the 
evolution of concentration in the member  states of the European 
Community. 
These reports were  compiled by  the different national Institutes and 
experts,  engaged  b,y  the Commission  to effect the study programme  in 
question. 
Re&Qrding  the specific and  general interest of these reports and  the 
responsibility taken by  the Commission  with regard to the European 
Parliament,  they are published wholly in the original version. 
The  Commission  refrains from  commenting,  only stating that the 
responsibility for the data and  opinions appearing in the reports, 
rests solely with the Institute or the expert who  is the author. 
Other reports on  the sectoral programme  will be  published by  the 
Commission  as soon as they are received. 
The  Commission  will also publish a  series of documents  and tables of 
syntheses,  allowing for international comparisons  on  the evolution of 
concentration in the different member  states of the Community. THE  DANISH  PHARMACEUTICAL INDUSTRY 
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This analysis of the Danish pharmaceutical trade has  taken place 
during 1974,  and it is one  of a  number of analyses of a  similar 
kind which are made  or have  been made  at the  instance of the 
EC  Commission in each member  country of the  Common  Market in 
order to analyse  the relationship between concentration and 
competition.  A knowledge  of this relationship is useful in 
connection with the administration of the  provi.sions  of the 
Rome  Treaty as  to  competition,  viz.  the articles 85  to 90. 
In  1974,  there have  been made  analyses  of three trades in Den-
mark: 
(1)  Radio  and  Television (ISIC  Sllb-group  3731) 
(2)  Electric Household.  Appliances  (ISIC  sub-group  3722) 
(3)  Drugs  (ISIC  sub-group  3194) 
These  trades have  been  selected. because  they 
(1)  have  a  considerable  size 
(2)  are not monopolized 
(3)  do  not have  an atomistic  structure  .. 
In Denmark  the  analyses have  been made  by 
Professor,  Haster of Economics,  Th.  Herbor~ Nielsen  .. 
Lektor,  Master of Economics,  Jens Vestergard  and 
Adju11kt,  }1a.ster of Economics,  Niels J0rgensen. 
This  analysis has  been made  by 
Adjunkt,  Master of Economics,  Niels J0rgensen 
Inntitute for History and  Soci.al  Science 
University of Odense. 
The  analysis has  been  translated from  Dan.ish into  2. 1~nc11sh b:r: 
stud.  lin~. mere.  3ir~cr Andersen 
T3':l....-(,~l  o,n0·~ gl··o-! on  ]•  ~-,.-,•-;,,..-. 
.1.1c.,.;.~l_!.""*..J.-\.:>-.&.  c.}).  __ \··-'-'  - J-!.J..:lLV  .. U -2-
Summary  and 1:1ain  Conclusions 
The  object of the present analysis of the  D~~ish pharmaceutical 
trade for the period 1968-1973  has been to describe its structu-
ral development  and to give  an  estimate of its development  of the 
near future  on  that basis.  This has  been  done  through  a  descrip-
tion of the general trends of the total Danish pharmaceutical sec-
tor,  a  more  detailed description,  quantitatively as v1ell  as  quali-
tatively,  of the Danish pharmaceutical industry and  the  develop  .... 
ment in its concentration and  through  a  description of the  com-
petitive situation for 8  important product markets. 
Section 1  is.a brief introductory section whose  main purpose is 
to delimit  the enterprises included in the Danish pharillaceutical 
industry and  to  delimit the final products  conceived of i.n  the 
following exposition as pharmceutical products.  This  section also 
states which  sources have  supplied  information to  the  analysis. 
Section  2  is a  general section dealing with the essential develop-
ment  trends.  Firstly,  the  total production of pharmaceutical pro-
ducts in Denmark is described,  and it is ascertained that it has 
grov.'Ti  considerably,  i.e. almost  doubling during the  period.  Second-
ly,  "'lle  deal with the  development  in the  delimi  tea.  trade.  1?rom  1968 
to  1973,  there has  been  a  vigorous  increase in both  t·urnover, 
number of employees,  as \·:ell as  \vage  bill, but it is pointed out 
at the  same  time  that both  the wage  bill and  the  turnover have 
gro,;!n  considerably more  than  the number  of employees  c  The  number 
of enterprisee in the  trade has  been almost unchanged  over the 
per1odo  Follo\,.ring  these  trade  statements there is a.  more  detc..1J ed 
description of the r;J.EFA-enterprises.  It appears  from this descrip-
tion also  tl:.ai:  the  proouction per em.p1oyec  has  gro,:m  consiclere.h1y. 
It appea.rs  moreover,  :from  a  distribution of the  employees  on  f·  ..  rnc-~ 
ti~ons that the  phar:mceutical enterprises employ  an  i.rnportant  part 
of tb.eir erllployces  in  researc~1 and control departments.  rrhirdly, 
the  c.evelo1)ment  in the  Danish  foreign  tracle  v;i th pharmaceutical 
~ 
p:eod1.1cts  is describedo  It a1)pears  from  the  tabulations that  1n:.ports 
as v.rell  g~1  ex·r_)orts  have  sho\'rn  a  vi  fO:r·ous  gro·v.rth  where  both  ha.~;c-: 
almost  doubled,  but  eY:})OTts  ha""~tc,  hov.rever  ~  exceeded  ·Lw_ports  to  ;1~.1 
ever  la~ger e~tent~ It is pointed out that the EC-countries l1ave -3-
the  largest dominance  as far as  imports  are  concerned,  especially 
\'lest  Germany  ancl  UX,  -v1hile  Scandinavia,  Sv:eden especially,  is the 
most important export market  ')f the  pharmaceutical industry.  Finalr• 
ly,  section 2  shows  the  development in the Danish  consumption of 
medicine.  v!e  see also here  a  viborous increase,  and.  it appears  tha-: 
the  gross  turnover of the pharmacies has  grovm  by more  than  50 
per cent. It also appears  that the main part of the medicine  cons-w:::-· 
ed  are pharmaceutical specialities and  the part "'rhich is subsidized 
is very large.  At  the  same  time,  hov1ever,  a  comparison of pr5.ces 
shov1s  that the prices of drugs have  gro·,m  less  than.  the  average 
of consumer goods. 
Section 3  contains  a  descriution of the  develournent in various  -- ~  -
concentration measurements  and  an  evaluation of the  future  develo~J-· 
ment in the concentration in the Danish pharmaceutical industry. 
it appears  from  the  development in the values  of the inequality 
indices - the coefficient of variation,  the  Gini  coefficient,  the 
Herfindahl-Hirschmann index e.nd  the Entropi  index - that the trade 
has  seen a  grol;Jing inequality betvreen its enterprises,  buton the 
other hand that this increase has been relatively slight,  The  in-
crease is mainly due  to the fact  that the largest of the  enter-
prises haveall  gro\·m,  vthile  the  small enterprises have  stc:.gne  .. ted. 
Tr..~.us  it appears also  from  the  various  concentration ratios that 
tile  largest of the trade's enterprises account  for  a  slightly larr,-
er share of both turnover as  v.rell  as number  of employees  and  •,vage 
bill. On  the  ot·hcr hand  this increase is very modest.  This mea.ns 
in other v1orcts  that it is a  shift bet1:1een  the largest of the  en-
terprises \'lhlch is due  to  the  gro\·Jing  ineq_ual.i ty vri thin the  trade 
as it expresses itself in the inequality measurements.  This is 
also  confirmed by the  Linda inc1ex values which  shov1  a  considerable 
increase over the period. 
It is also ascertainecl in this section that  the  Danish  pharmaceu--
tical  i~dustr-y is mainly Danish-o·vmed,  that most  of the  enterpris-
es are  f~'"T)ily  joint stock  co~p8TLiest  and  that it,.  by  and  l2..rge,. 
is the  same  c;::1ter:prises  which  are in the  trade in 1973  tlJ.at  ·were 
also in tl";e  trade in 1968  ..  On  this basis  and .. on  the basis of the 
development  trends ill product  developmen.~.:.,  prod"'J.ctlon  costs,  re  ... 
search costs  a.n.rl  ms.rketing costs  \·Je  ::J.1.:'.Dt  conclude  that  a  ft:;,:c-tr..er 
COY1centrc:.tion  of the  Danish  -rl1a:rlliacev.tical industry is to 1e  ex. ... - 4-
pected in the years to  come.  This concentration need  not nece-
sarily take place in the way  that Dru1ish  enterprises are bought 
by the large foreign combines; it may  also be  caused by fusions 
and  an integrated cooperation especially within research.  We  also 
conclude that the share of the Danish pharmacies  of the total 
production will be falling until it stabilizes at a  somewhat  lower 
level. 
Section 4 is a  qualitative description of the Danish  pharmaceutical 
trade.  After a  brief exposition of the  existing structure with 
producers,  im~orters, whole-salers,  pharmacies,  and public  con-
trol,  the  seven largest producers  of medicine  are  described.  The 
main product lines are  stated,  ho'"  conditions as  to  O\Ame.rship  are 
a.'tld  which  subsidiary and  sales  companies  they have  established 
during the years.  Finally, it is stated which product  groups  the 
enterprises produce  or sell apart from medicine.  It appears  from 
this description  that the industry is Danish-owned,  that the in-
dustry is internationally oriented,  and  that there is only  a  limit-
ed diversification - the enterprises are largely pure  pharmaceutiu 
cal factories.  In a  later section we  also  show  the  close  connec-
tion between the Danish and  the  Swedish pharmaceutical industries, 
Finally,  three  small sub-sections indicate  ~n1ich foreign  enterpris-
es are represented  on  the Danish market  and  how  the \·!holeS8.l.e  trad.e 
and  the retail trade are  org~~ized. 
Section  5  is an analysis of a  number of different product me.rkets. 
\
1le  open,  hoVTever,  with  a  discussion of the  general competitive 
si.tuation for pharmaceutical preparations. It is noted that there 
is a  large number of product markets,  w.d  that the  indi  vitlual pro-
ducts have  a  relatively short existence.  Therefore 9  competition 
takes place partly by  furthering existing products,  po.rtly by  la:v.nc'r:.-
ing new  preparations.  The  marketing of new  products is different, 
hc,,vever~  according to  the  degree  of innovation ·whieh  the  prepar8.  .... 
tion introduced repr:esents6  The  registration of pha.l:'flla.ceutical 
s:~Jecia.li tiess  includ1ng thc  problem vri th  names~ is stated as  &"'1.otLe:" 
aspect in the  evaluation of the  competitive  s1 tuation in  tJ~te  :i.:tl.di-
vidual nroduct markets. It is ind.icated  tb.8.t  the  phe.rmacics  have 
o.  preferent.b. l  posi  tiOl1,  2.:'1d  tr.c.t  rest::.~ictio:r..s  e.s  to  ne!:les  :nay 
have  limited the  nurr:oer  cf suppl.ie:c-:.1  on  the  incl.iv-.idueJ_  :narr01H pro-
duct markets. -5-
Then  8  product markets  are  a..11alysed:  psychopharmacological  drugs, 
tranquilizers,  antibiotics,  vitamins,  analgesics,  contraceptive 
pills, insulin and  sulphon~~ides,  and  CR4  and  L4 are calculated 
for the last three years.  In all product markets  a  minority of 
suppliers are predominant,  yielding a  relatively high  CR4•  In one 
individual market  there is an acutal monopoly.  It is typical,  ho':T-
~-~~ that different enternrises are predominant in th_e  diffe~ 
If£9d.uct htarkets,_§_o  that no  single enterorise  Ca.l1.  be  said to have 
any  dominant  influence  on  the  total  D~~ish market  •. -6-
1. Delimitations 
1.1.  Delimitation of Enterprises and  Firms Within the  Trade 
To  delimit the  enterprises of the trade  the  same  principles 
as those  employed by the National Bureau of Statistics at the 
making up of Industriatatistik have  been used.  Cf.  for instance 
Industristatistik 1971,  Statistiske IJieddelelser 197  4,  3. 
This delimitation has been chosen to be  able  to use  to  the 
widest extent possible the  surveys and results of the official 
industrial statistics as  a  starting point  and basis for com-
parisons. 
Enterprises manufactu~ing drugs are delimited along the  follow-
ing lines: 
(1)  An  enterprise is understood as  a  local unit  exercising 
an  economic  activity. If a  local unit  exercises several impor-
tant activities,  and  there are no  possibilit1es of registering 
any distinction of them,  the activities are registered under 
one unit,  and  the main activity forms  the basis for the class-
ification of the unit in the  trade. 
(2)  Only enterprises with at least  6  \torkers  or salaried em-
pJoyees are considered industrial enterpriseso 
(3)  Only enterprises achieving the main part of their value 
added  through productive activity are  considered industrial 
enterprises. 
(4)  Only enterprises achieving the r:1ain  part of their turnover 
within the  final products mentioned in 1.2.  are included in 
trade  3194  - pharmaceutical factories. 
This  delimitation implies that no  pharmacy is included. 
The ·firms of the trade are  delimited along the  follov:ing lines: 
A firm is understood  aE  a  corporation aggregate  exerclsing 
one  or several  economic  activities in one  or several local 
units.  Thus~- a  firm  may  comprise  one  or several en  te:rpri ses. -7-
In the trade production of drugs  are  included  firms  whose  main 
activities fall within the  production of the  final products 
mentioned  in section 1.2. -8-
1.  2.  Delimitation of the Fina·l  Products of the Pharmaceutical 
Trade 
Final products are understood  as  goods  or services supplied 
to others. 
Drugs  are  found  in chapters  29  and  30  in the Brussels nomen-
clature or in chapter 54  in the  SITC  nomenclature. 
The  final products of the trade consist of the  following main 
product groups: 
Vitamins  and  provitamins 
Penicillin,  st.reptomycin,  tyrocidin and 
other antibiotics 
AlKaloids  of opium,  cocaine,  quinine  and 
other vegetable alkaloids,  their salts 
and  other derivatives 
Hormones 
Glycosides  and  derivatives 
Organotheurapeutic  glands  and  other or-
gans  and  their extracts 
Bacterial products,  senun and vaccines 
Remedies 
Cotton ·wool  and  the like impregnated or 
coated with phramceutical preparations or 
in retail sale packages 


























The  main  group ,.,hich \'Till  be treated most  detailed in the  fol-
lo\•Iing  is BTl!  30.03 which is also called pharmaceutical  spe-
cialities. -9-
1.  3.  Infor!nation and  Statistical  ~·-'La~ erial 
The  Danish pharmaceutical industry has  turned out to be  an 
extremely unapproachable  trade.  None  of the enterprises have 
p~blished their accounts  before 1973  after which date it is 
prescribed by the  lav1  to  do  so,  and  only a  few  small enter-prises 
have  been prepared to fill in the questionnaires  submitted to 
them.  In return some  importers of drugs  and  sales companies 
have  supulied  some  information.  Therefore,  the analysis is 
based  to  a  '"ide  extent  on  information and  statistical material 
from  other sources than the actual enterprises. 
To  a  wide  extent,  section 2  is based  on statistical material 
from  the publications of the national Bureau of Statistics: 
I~dustristatistik (Industrial Statistics) 
Produ~:tionsstatisti 
1 .<:  (FroO.uctlo.n  Statistics) 
Import- og  eksportstatistik  (Import  a.lld  Export Statistics) 
and  from  the publications published by the  trade associations 
lv1EFA  and  the Danish Pharmaceutical Chemists'  Assoc1ation. 
Section  3  is based  on information  from 
Aktiesels1cabsregistret  (The  Danish Register of Comp&""lies) 
Industristatistikken (Industrial Statistics) 
Greens  dal1ske  fonds  og  a
1<:tier  (Green's  Dantsh  Stocks  and  Shares) 
J:om-pas  Tianmar~\: 
The  50()  larr;est  enterpr:ises  in Denmark 
Submitted questionnaires  ru1d 
Intervie,:rs  v.ri th trade  ex~)erts  and  managers. 
A~art from  the  above-mentioned,  section 4  is based  en  infor~ation 
from  71ublished  renorts  in  Denmar'::  ana  S1!:edr:!n  as  to  st:rpply  of 
drugs  and  announ.cements  from  the  r.~onouolies Authorities plus  a 
publication published  b:y  I,1EFA  in 1973:  40  ::tears  with  drugs. 
The  ?...nalyscs  in section  5  are  based.  on  the  turnover figures 
from  selected Danish  pharmacies  and.  on  information  from  the 
national  He~lth Service. - 10-
2.  Develonment Trends  In the Trade 
2.1.  The  Production of Pharr;:aceutical Products 
Table  2.1.  shows  the total Danish production of pharmaceutical 
products  for the period  1968  to  1973.  Pharmaceutical products 
are understood as  -pharmaceutical specialities and  bulk  goods 
as delimited in section 1.2. 
The  table  includes the  ~reduction of this type  of products  for 
the total Danish industry whether the  enternrises in question 
are classified under trade  3194  or not. 
The  products are  stated in prices  ex factory,  and  during the 
neriod these prices have  risen only slightly. It appears  from 
the table that the  production has  almost  doubled  during the 
-period  and  that  the main  -part  of the production are manufactured 
goods  - pharmaceutical specialities.  ~~he  producti.on of drugs 
of the Danish pharmacies  is not  i:cluded in the  figures. 
2.2.  The  Pharmaceutical  InduRtrv  (Trade  3194) 
Table  2. 2;  sho;.rs  the  development  in the Danish pharmaceutical 
industry du:ring  the period 1968-73.  The  number of cnte:r:pl:ises 
is almost  uncha_n_ged,  and it is also  to  a  wide  extent the  same 
enterprises \vhidh  existed in 1963  that are in the trade to-day. 
Furthermore,  the  enterprises have  almost  the  same  relative 
sizes to-day as  in 1968.  The  largest enterprises are all mem-
bers of the  trade  association I·'tE}"'A,  and  these enterprises \·!ill 
be  described in detail in the  following. 
The  total turnover,  incJ,J.ding  about  15  per cent  trade turnover, 
has  alcost trebled during  tl1e  ':}eriod,  vrhile  the  number  of  em-
nloyees has  only  [~I'O'\·.m  from  3,126 to  6, 020.  In other words,  the 
tul·n')Ver  per  emnloyee  has  gro\·:'11  considerably as it also  a:Y~ears 
fi·o::rl  the  table. 
The  to-~al \·:age  bill,  bo~.-.rever,  has  more  thar1  trebled  d1.1.ring 
the  6  years.  This  development  is a  result partly of a  vigorous-
}~'  increasing Vla..';;e  lev(;]_  in Dcn112.rk  e;enera1ly  and  partly of the 
fact that  tbe  enterprises  e~ploy a  group  of highly qualified -11-
employees  -..·:hose  salaries have  grov.rn  more  than  the  average  wages. 
If \·:e  look at  the  l\IEFA  enterprises alone,  table  2. 3.  also illu-
strates the increased productivity in the  trade  and  by its group-
ing of the  employees  table  2.4.  illustrates the fact  that  a 
very  substantial part of those  employed  are  salaried emplpyees. 
Finally,  tables  2. 5.  and  2. 6.  shoHs  the  development  1n  tv:o  of 
the  most  disputed cost  i terns.  Table  2. 5.  sho\·rs  a  substantial 
increase in the HEFA  enterprises'  costs to public relation and 
advertising from  1968 to  1972,  and table 2. 6.  sho\vs  an  equally 









































































































































































































































































































































































































































































































































































































































































































































































































































Table  2.3.  The  Production of Drugs  of the MEFA  Enterprises  1968 
and  1972. 
1968  1972 
The  production of drugs of 
the  MEFA  enterprises  380  660 
million Dkr 
Production personnel  2,411  2,504 
Production value per employee 
in the production  158  264 
1000  Dkr 
Source:  Medicinsk  For~~ 1973,  no.  3. - 15-
Table  2.4.  The  Personnel of the MEFA  Enterprises  1968  and  1972 
1968  1972 
number  %  number  % 
Research  712  17  785  18 
Production  2,411  58  2,504  57 
Control  221  5  262  6 
Sales  428  10  424  9 
Administration  421  10  427  10 
Total  4,193  100  4,402  100 
So~rce: Medicinsk  Forum  1973,  no.  3. - 16-
Table  2.5.  Direct Costs to Public Relation and Advertising of the 
MEFA  Enterprises 1968  and  1972. 
1968  1972 
million Dkr  %  million Dkr  % 
Advertisements  2,882  22  4,709  24 
Printed papers  3,026  23  3,401  18 
Pharmaceutical  advisers  5,368  40  8,257  43 
Pharmaceutical tests  1,128  8  1,195  6 
Other  958  7  1,810  lOt- Total  13,362  100  19,372 
Table  2.6.  Research  and  Development Costs of the  MEFA  Enterprises 
1968  and  1972 
-·--·--------
1968  1972 
Research costs  45  65  million Dkr 
-
Source:  Medicinsk  Forum  1973,  no.3. - 17-
Table  2.7.  shows  Denmark's  imports of pharmaceutical products 
distributed on  EC  member  countries for the  period.  Here,  the 
EC  countries account for a  substantially larger share  than 
exports  do.  In 1973  almost  50  per cent  of the  imports  came  from 
the  enlarged Common  Market. 
Also with respect  to  imports  are vi est Germany  and  UK  Denmark's 
most  important  trading partners within the  EC  with exports to 
Denmark  in 1973  of 92  and  76  milll.on Dkr,  respectively.  It 
appears  from  the table,  furthermore,  that the exports to Den-
mark  forthe  other countries within the EC  have  stagnated. 
Outside  the EC,  Switzerland,  USA,  and  Svreden  are  important 
exporting countries. 
If table 2.7.  is compared  to  figure  2.1. it appears that the 
' 
growth in imports is based  mainly on  bulk  products,  while  im-
ports of pharmaceutical se-pcialities are  stagnant  .. 
The  growth in both imports  as well  as  exports illustrates the 
internationali?.ation that has  taken place in the Danish pharma-
ceutical industry as  a  consequence  of a  pronounced  specializa-
tion in  ~reduct groups. - 18-
2.3.  Danish Exnorts  and  Im~orts of Pharmaceutical Products. 
The  Danish pharmaceutical industry is a  pronounced  exporting 
industry. If we  compare  table  2.8.  which  shows  Danish  exports 
of pharmaceutical products distributed on  EC  countries for 
the  period,  with  table  2.1.  which  shows  the  total Danish  pro-
duction of these  products,  it appears  that an  ever larger share 
of this production is exported. 
It appears  from  table  2. 8. ,  furthermore,  that the  enlarged.  EC 
takes  a  substantial part of these  exports,  but that the  share, 
however,  amounted  to  about  28  per cent only in 1973. 
In contrast,  figure  2.2.  clearly illustrates where  the  most 
important markets  of the Danish pharmaceutical industry are 
situated - viz&·  in Scandinavia.  In  1973  the  exports  to  Sweden, 
Nor\vay  B.nd  Finland totalled 191 mi1lion Dkr or almost  as  much 
as  total exports  to  the  enlarged EC.  Apart  from  EC,  USA,  Spain, 
and  S\·Ti tzerland are  large recipient countries. 
With  69  million Dkr West  Germany  is by far the  largest reci-
pient country of the  EC  countries  followed  by  UK  with 36  mil-
lion Dkr.  As  a  whole  the  exports  to  the  individual EC  countries 
have  grown  steadily during the  period. 
The  rest of the  exports is distributed on  a  large  number  of 
countries both in the rest of Europe  as well as  Asia,  Americas 
and  Africa vThich  also  appears  from  figure  2. 2. 
Table  2.9.  shows  the  distribution of exports  on  groups  of pre-
parations.  lJ.'he  group penicillin and other antibiotics is  clear-~ 
ly the  most  importru1t,  but it must  be  noted  that the  exports 
of insulin totalling 103 million Dkr  make  Denmark  the wor1d's 
largest exporter of this product. 
Figure  2 .1.  shovs,  among  other things,  the  exports  of phe.rma-
cutical specialities which  amounted  to  about  42~5 million Dkr 
in 1973.  If th1s  figu:ee  is compared  with the  figu.res  in table 
2.2.  for total exports,  it appears  that  the  share  of bulk  pro-















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure  2.2.  Danish Exports of Pharmaceutical Products  in 1973. 
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Table  2.9.  Danish Exports of Pharmaceutical  Products  in 1973  Distri-
buted On  Groups  of Preparations. 
Groups  of preparations  million  Dkr 
Penicillin and other antibiotics  218 
Insulin  103 
Vitamin  and  vitamin preparations  87 
Sulphonamides  52 
Psychopharmacological  drugs  51 
-
Otl;ler  210 
~ 
Total  721 
Source:  Danmarks  Statisti~c.  Danmarks  vareindf0rsel  og vareudforse1. - 24-
2.4.  '!'he  Danish Consumption of Drugs. 
The  pharmacies are  the retail outlet for drugs,  cf.  section 4. 
In 1972  there were  348  pharmacies in Denmark  which have  a  num-
ber of chemist's  shops  attached to  them.  It appears  from  table 
2.10.  that the number of pharmacies has  been slightly falling 
during the  period under consideration.  The  gross  turnover of 
the  parmacies,  however,  has  gro\vn  during the  same  period by 
more  than  50  ~per cent from  617  million Dkr  in 1968  to  962  mil-
lion Dkr in 1972.  In 1973  the  gross  turnover of the  pharmacies 
reached 1,016 million Dkr exclusive of V.A.T. 
Most  drugs  for human  consumption are  prescribed by doctors in 
a  prescription,  the recipient then fetching his goods  at the 
pharmacy.  It also  appears  from  table  2.10.  that about i  of the 
turnover of the pharmacies is turnover deriving from  prescrip-
tions.  Table  2.11.  shows  the distribution in per cent of pre-
scriptions on pharmceutical specialities and  on other drugs, 
i.e.  drugs manufactured by the  pharmacies.  It will be  seen that 
the  share of pharmaceutical  drugs has  been  steadily gro\'!ing  during 
the whole  period both as  to  nw~ber as well as  to  amount. 
It appears  from  figure  2.4.  that the  turnover of the Danish 
pharmacies totalled 993,8 million Dkr inclusive of V.A.T.  in 
1971  ..  Drugs  prescribedaccountcd  for635  million Dkr  and  of these 
502  million Dkr were  entitled to  subsidies.  To  arrive at the 
total annual  expenditure  on  drugs  for human  consumption it is 
necessary to  further add  the hospital supplies of 71,4 million 
Dkr  and  the drugs  sold by the  chemist's  shops  totalling lf4,4 
million Dkr.  The  hospital dispensariest  !'lowever,  make  purchases 
of drugs  directly from  producers  and  importers  and  hav-e  a  pro-
duction of their O\·:n.  This  turnover is estimated to  be  tv:ice 
as  lare;e  as  the  pharmacies'  sales to  the hos-pitals.  If th.ese 
items are  added it apnears  that in 1971  the  total consumption 
of drue;-s  for human  consum::-~tion totalled about  1,000 million 
D1cr. - 25-
~ith the purpose of analysing the  consumption of drugs  in Den-
mark  in connection with  a  revision of the  system of subsidies 
to drugs  the prescriptions received by every  pharmacy  during 
one  day at the  end  of 1971  v:ere  analysed.  By  dividing the pre-
parations prescribed in therapeutic  groups it turned out that 
the distribution of the  consumption in Denmark  in 1971  was  as 
illustrated by  figure  2.5.  The  hatchings  indicate the  subsi-
dized nart of the turnover.  In 1971  the  subsidies to that part 
of the  drugs which were  entitled to  subsidies  amounted  to  75 
per cent.  Thus,  the public  expenditure in 1971  to  drugs  en-
titled to  subsidies totalled i  of 502  million Dkr = 375  million 
Dkr. 
Figure  2.3.  shows  the  development  in prices of some  important 
Danish-produced preparations.  If these  prices are  compared 
to the retail price index for the  same  period it appears  that 
while the  consumer price index  grew  by  about  25  per cent,  the 
















































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.3.  Some  prices of drugs  in relation to retail price index 








Retail price index  1964=  100 
1970  1971  1972  1973 
The  8  most  sold  Dan~sh-produced preparations  1973. 
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993.8 rnio kr. 
~- Veterinary drugs 
~  (47,0 millidn Dkr) 
··] Hospital supplies 
(71,4 million Dkr) 
I)  Branded  goods  ( toiletware,  etc.) 
_}  (7?,0 million Dkr) 
l 
.
l}.  Drugs  sold by chemist's  shops 
1 (154,4 million Dkr) 
~ Drugs prescribed without  subsidy 
)  (132 million Dkr) 
} Drugs  prescribed ·with  subsidy  I (502 million Dkr) 




















































































































































































































































































































































































































































































































































3.  ~rhe  Develonment  In Concentration In  the  Danish Pharmaceutlcal 
Indust~J. 
3.1.  The  Development  In Various  Concentration Indices  Over the 
Period 1968-73. 
Section 2.2.  gave  a  description of the  Danish pharmaceutical  i~du­
stry for the  period 1968-1973.  This  section will further illustra-
te this development  by means  of a  number  of concentration measure-
ments,  each of which  deal with different aspects  of industrial 
concentration. 
These  concentration measurements  give  an idea of the  distribution 
of size of the  enterprises included in the  trade~  as  we  assume 
that size is a  reasonably  good  indicator for the  position or power 
of an  enterprise.  We  can  disting·v.ish  between measurements  of an-
solute  concentration and  :i,nequality measurements.  The  former is 
a  measurement  of e.g.  the  part of the  total turnover referable 
to  a  small number  of large enterprises,  while  the  latter is  2. 
measurement  for  that percentage  of the  total nu.lnber  of entcr):'rir5es 
in the  trade  controlling a  certain percentage  cf e.g.  the  total 
turnover. 
~his a.nalysis  ap-plies  4  measureme::nts  for  j_:r.(;quali  t~:r:  the  coc ff:i-
cif~nt of variation,  the  Gini  coefficient,  the Herfj_ndahl-Elrsch-
mann  index  a~d the Entropi  index,  v.rhile  t 1:.:o  measurements  concern 
absolute  concentration,  vlz.  tl'.te  coneentration ratio  and  trH.;  Lin-
da index. 
In appendix  A there is a  more  detailed  expl8-LYJ.ation  of the  indi  vi-
dual concentration measurements.  The  2ppcndix contains also  the 
main  tables  for the  respective  indices. 
Ineoulitv  ~e~surements  ______ .... _,... ___  ... *_......~- ....  -~---..-.. - -
The  c o  e ff  j_ c i c  r: t  of v a r i  21. t i  O!.&_  is a  me a S'!J rc  7  P r: t  for  the  re  1 at  i  Y e  - .... ~-----~------~~--·~-------~--
spreading of  t~1e  various variables  aB  .it is  the  sta-n.da:rd  de-..,r1e.tio:c 
divided  by  tbe  mean  VG.lue.  This  rna];:es  i·t.  alsv a  ffiea.Ru::rcm.ent  fo:t"'  t}ls 
inequality within the  trade.  The  smaller tbe  coefficient of  va~l~-
cr will be  'the concentration'. - 32-
The  development in the  coefficient of variation for the  three 
variables is shown  in figure  3.1.  For all three variables,  the 
coefficient of variation has  been increasing at first,  then  slight--· 
ly falling.  This  somewhat  growing inequality in the  trade is an 
indication of the fact that the largest enterprises have  gro~1 
larger,  while  the  small enterprises have  stagnated.  The  vigorous 
increase in 1971 is mainly imputable  to  the  fact  that Novo  is 
classified under the pharmaceutical industry that year.  The  strong-
er increase in the variable  '-v1ages  and  salaries'  may  probably be 
explained  by  the fact  that only the  largest enterpriseshave defi-
nite research departments with highly salaried staffs  and that 
the  shares of wages  and salaries of the largest enterprises,  there-
fore,  have  groJNn  in relation to  those  of the  small enterprises. 
The  Gini  coefficient is also  a  measurement  for spreading. It is 
a  measurement  of the  degree  of unequa.l  sizes of the enterprises 
of the trade.  If the  Gini  coefficient is 0,  it means  that all 
the enterprises of the  trade  are  equal as  to size. It gives no 
indication,  however,  \•Thether  there are  20  or  200  enterprises in 
the  trade.  The  Gini  coefficient is a  sunming up  of the  informa-
tion conveyed by the  Lorenz  cu1~e. 
The  development  of the  Gini  coefficient for the three variables 
is sho\-m  ln figure  3.2.  Like  the  coeffj_cient of variation,  the 
Oini  coefficient also  sho;·Js  a  gro·v1ing  j_nequali  ty over the period. 
Here,  too,  the addition of a  large enterprise means  that the  co-
efficient  jumps  to  a  higher level \iherc it stabilizes.  Apart  from 
that there has  been  a  moderate  increase in inequality. 
The  Herfinoahl-Hirsc"h.mann  index is a  concentration measurement 
which  takes  into consideration both the  nu..vnber  of enterprises l.n 
a  trade  and.  the inequality of si.ze  between  them.  Other things 
being eq·ual,  a  larger number  of enterprises in the  trade  &J.d/or 
a  larger equality will diminish the  index value.  As  data ·bo·t;h  about 
inequality c.nd  number  are  combined,  a  comparison of the  vari.ous 
index values  i.s  most  lilcely to make  sense,  when  the  number in the 
trade,  as  ~ere, is fairly constant. 
IrreGpective  of the  n1J::aber  of enterprisss in tlie  trade,  the  index 
value will approach  1000 when  the  largest enterprise'  r:;  shn:r·e  of 
the  trade  approaches  100  per  cent~  ~he  ~i.nimus value  of  t~c index - 33-
will be  reached when  all enterprises are  of the  same  size,  and  this 
limit varies with the number of enterprises. 
The  development in the  index values for the Danish pharmaceutical 
industrJ is given in figure  3.3.  The  development is largely the 
same  as for the  previous  two  indices. 
The  Entro:Qi  index i.s  the  fourth inequality measurement,  and  the 
measurement  that attaches most  importance  to  the  small enterpris-
es.  As  it will appear  from  figure  3.4.  the values have  been fair-
ly stable over the period. 
Concentration Measurements 
The  concentration ratio  and  the  J,inda -index belong together. 
Whereas  the  concentration ratio gives  a  simple  exposition of the 
paucity  of a  trades  thus  giving an  idea whether it is clearly do-
minated by  a  small  group  of enterprises,  the  Linda index measures 
the relatlve sizes of the  enterprises for which  the  concentrr:...tion 
ratio has been calculated. 
The  concentration ratio is obtained  from  the  concentraticn curve 
of the  trade  ..  This  curve is dravrn in a  system of coordinates,  v{here 
the absclssa axis indicates the  number  of enterprises - from  the 
largest to  the  smallest  - while  the  ordinate  a:x:is  indicate the 
cumulated percentage  of the variable  for the number  ofenterpTise[-; 
plotted on  the abscissa axis.  The  hcdGht  of the  curve  above  any 
point x  on  the abscissa axis measui·es  the  percentage  of the  total 
size of the  trade  accounted  for by  the  x  largest enterurises- i.e. 
the concentration ratio. 
For the  Danish  pharmaceutical  in.dtJ.stry,  the  curve is vigorousl:t 
rising from  left to right,  i1.1 us  indicating a  fairly  conce~1tra:tcd 
trade.  This  appears  from  fiGUres  3.5"  to  3.7. It aJ.so  appe2.rs  tl;.at 
the  concentration curves have  shovrn  o.lmost  no  shifts for  the  .ll,}D::·ce 
variabler~ over the  period. 
As  men-cioned,  the  J.,inda  inc1cx.  is a  mcasu.:ee~uent for  the  inequality 
v,ri thin the  vari_ous  spot tests.  }!'or  alJ.  yee.x·E  ·2.nd  fer all variable:::; - 34-
three variables is sho\vn  in  fi~~re 3.8.  At  firstf it is slightly 
increasing and  then it jumps  to  a  higher level,  again as  a  con-
sequence  of the fact  that Novo  enters the  trade.  In contrast,  there 
are  slight differences as  to  for which  spot tests the Linda i.n-
dex  assumes its minimum  value,  but here,  in return,  the  fluctua-
tions are not  so  pronounced as  for the maximum  values.  The  deve-
lopment  i~ the minimum  values  for the  three variables is sbo\m. 
in figure  3 • 9 • - 35-
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Figure  3.7 
The  Concentration Curve:  \·!ages  and  Salaries 
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~.2.  An  Estimate of the  Development 1vithin the DP..nish  Phar-
maceutical Industry 
For several reasons  the production of drugs must  be  assumed 
to be  suitable for Denmark: 
(1)  The  country has  an  educational level which makes it possible 
for a  pharmaceutical industry to recruit a  sufficient qualified 
personnel. 
(2)  The  country has  a  well-established pharmaceutical statistl-
cal material and.  a  developed hospital service. 
(3)  As  far as weight  and  quantity are  concerned,  the  corH:sump-
tion of raw materials is modest. 
The  negative  factor is that Denmark  is a  small national market 
area whose  dema.r1d  is not alone  R-ble  to  support an  independent 
pharmaceutical research. 
The  Danish pharmaceutical industry as  delimited by  the Natio-
nal Bureau  of Statistics consits of a  small number of rela-
tively large  enterprises  and  a  large number  of small enter-
prises. 
The  total number  of enterprises has  not  changed very much 
during the last  6  years,  a.nd  the  structure has not  changed 
either. It can also be  ascertained that tbe  largest Danish 
pharmaceutical factories  are  the  same  as  those  \·lhich  have 
been  prec1ominant  c:iuring  the  last 15  to  20  years.  Tlrns,  the 
concentration has  increased,  because  t}le  largest enterprises 
have  experienced  a  substantial  gro~.-:th,  vihile  the  mediu:-:1-sj_z:ed 
and  small  enterprises are still at the  srune  level. 
The  main part of the  Danish pharmaceutical industry has  always 
been  on  Danish hands,  and most  Danish  enterprises are still 
managed  by  descend.:mtfJ  of the  original ovn.1ers. 
The  grov1th in the  pharmaceutical industry is ma.:tnly  :::  result 
of the utilization of the lat8st advr1.:nces  \>'i th.i.n  the  pharma-
ceutical :research:  antibiotics,  psychopha:r.Yuaco1og1ca1  drues 
D.nd  ora.l  contracepti'v8s  ..  In  acldj_tion 9  De:r.naar1;::  r.:.as  a  special 
advDn  tage  ln the  producti.on  of  ins11.l:!.n  b~~cause of the  -pre-- 45-
aence  of a  great number  of pigs within a  relatively small geo-
graphical area and  a  vigorously growing need  for vitamins. 
By  and  large  the latest pharmaceutical advances  are utilized 
by now,  however,  i.e. there is actually nothing new  about  the 
preparations appearing within the fields in question. 
Because  of that,  the  problems  faced  by the producers have  assum-
ed  another character: 
(1)  The  research must  be  applied to  other than the usual fjelds. 
(2)  The  marketing becomes  more  important. 
(3)  Advantages  as  to production may  become  decisive. 
During recent  years,  the  Danish pharmaceutical factories have 
made  fairly good  profits. It must  be  expected,  however,  that 
~hese profits will be  reduced  in the  years  to  come,  because: 
(1)  There has  been no  new  category of drugs  d.uring recent years 
to replace antibiotics,  psychopharmacological  drugs  and  oral 
contraceptives,  and  i.t  must  be  expected that remedies  against 
cancer and  colds "'ill be  long in coming. 
(2)  Higher research costs have  reduced  the  speed of appearan-
ces of new  drugs. 
(3)  It must  be  assumed  that  the prices of drugs will be  sub-
jected to an increased supervision partly from  the National 
Health Service  and  partly by the Honopolies Authorities  posRib-
ly taking over the price control.  A changed  system of subsidies 
for medicine with the  consequence  of highe:r  expenses  for  the 
consumers  may  clamp  do·i,n  the  consumption of certain categories 
of drugs. 
(4)  Endeavours  of the  enterprises towards  diversification will 
contril1ute to  the  equalizing of p:eofi ts,  because  nev.r  product 
lines may  have diffi.culties in reaching the  same  bigh level 
of profi  tabilj_ ty \vhich is tradi  tlonal in  the  production of 
drugs. 
Economies  of scale at the production stage is less 1mporta:nt 
in the  phaTmaceuticcl industry than in the majority of other 
•  ~  J... 
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In return,  the  costs for research and  development  and  for infor-
mation  and  advertising have increased during recent years. 
To  carry through  a  large research project requires  a  certain 
number of researchers  from  different disciplines.  The  number 
may be  60  to  100  men.  T,'linimum  requirements  of this type  imply 
that  small enterprises cannot undertake  certain types  of pro-
jects or that the project vrill require very much  time.  At  the 
same  time  certain indivisibilities im-ply  that the utilization 
of the capacity of the research department  may  be  increased 
by working  simultaneously at  several projects and  with doubling 
of certain functions. 
The  research activities is that paTt  of the activities of the 
pharmaceutical industry where  the advantages  of large units 
are most  evident,  and  these  advantages  have  increased during 
~ecent years.  Economies  of scale are increased by  the superiori-
ty which the  lar,se enterprises have  obtained  through better 
possibilities of a  distribution of risks by aiming at  several 
independent projects. 
It is assumed  in the  trade that it costs 15  to  20  million Dkr 
over  5  to  7  years  to  dev-elop  a  regular ne''' :product.  To  a  large 
extent,  therefore,  the Danish pharmaceutical industry has  had 
to consider Scandinavia its domestic  market~  ~his also appears 
from export  statistics,  cf.  figure  2. 2.  For many  preparations, 
satisfaetory sales in Scandinavia will not  be  sufficient to 
cover the  growing  development  costs.  In other ~ords 9  if the 
Danish phar;naceutical industry must  develop its own  preparations 
based  on its O\·Jn  research in the  future,  it will be  necesse.ry 
\"Ti th marketing/  establishing  j_n  a  n 1J_mber  of countries outside 
Scandinavia.  Of  course,  this ·vlill  engage  a.  number  of resources  16 
The  concentration vri thin the Danish ·pharmaceutical 1ndustry 
is relatively· small.  Tbis  LS apparently  due  to  two  nircumstan(;es: 
( 1)  There has  been no  gensrati0!1  pro  blell)S.  T·he  major~~  t~{  of the 
growth has  taken place  during  so  fe~ years  that there has  been 
no  al  tcrnation of generations  duri::.1g  that  pGriocL. 
(2)  The  results of the  enterprises have  been  so  ~ood that  they 
l!.a.ve  been able  to  fj_nGJ1.::;c  to  a  larz€  extent  the  e:-:I..IS'_1J.si.on  the:>l·-
selves. - 47-
At  the  same  time  competition has  been restrained to  some  extent 
by the rather restrictive  D~nish pharmaceutical legislation. 
There is much,  however,  pointing towards  an increased competi-
tion in the next  5  to 10  years,  both in form  of fusions  and 
buyings as \vell as in the  form  of increased cooperation betv1een 
both Danish  phal~aceutical factories mutually and  between Dan-
ish and  foreign pharmaceutical factories. 
First,  the research departments of the various enterprises are 
'too small',  cf.  above.  They are  able to  embark upon  a  limited 
number of projects only,  ~nd therefore,  the risk of a  lacking 
product development will be  great.  As  the research departments 
of the various Danish enterprises  do  not overlap to  any notice-
able extent,.and as  the  research costs,  as mentioned,  are rising 
the conditions  for a  concentration of the research are  favour-
able. 
The  necessity of increased exports  from  the  Danish enterprises 
also points  to\'!ards  an increased concentration in one  way  or 
the other.  One  possibility is fusions  of Danish enterprises, 
thus  reducing marketing costs.  Another possi  b5li  ty is the  buy·-
ing and  selling of licenses  from  and  to  foreign  enterprises. 
A third possibility are  joint ventures,  i.e.  a  Danish enter-
prise in cooperation with  a  foreign  enterprise  establi5ht~s a 
nev!  enterprise,  marketing for instance preparations manufactured 
by the Danish enterprise  in various  countries.  Thus,  the Danish 
enterprise contributes with the  preparations in the  new  enter-
prise,  v.;·hile  the foreign  enterprise contributes for instance 
with the  sales organization  .. 
A  third  circumstance pointing tol·Jaros  a  future  concentra.tion 
is the proprietary condi  ti.ons  of the Danish pharmaceut-;ica.l 
industry.  In the near future  an alteruation of generations in 
the  ma.nae;ement  must  be  expected.  It  j_ s  possible that  ·the  new 
generation  ·v1ilJ  further  fusiOns  or sales.  Up  to  nov:,  the  co-
operatio~1 v.ri thin the  t:!:·ad(:  1Hlc1  been  l~athe:r·  l:Lmi ted.  This is 
d -ue  +o  the  f'-:::.ct  t1•~-~- +:,a  larrrc  e~lte.,....p-rl· s-=·rt  l)'Y"'re  1.-.-='-d  •:~  pa-~-r~- V  •  -- Cl.  •- •. (.._.  V  IJ  . v  b  ·'  , J. _  ~  1, ..  t.:"J  --<:\ \  ·  iJ.CA.  <.J,  IJ  - ...1... 
archa1  rnr::tnagemcnt  vrhich  has  been :rcllJr:tant  to  take  np  nC'd  pro-
ducts  ,_.,td_ch  ha.d  :rJot  :ceD  <3r;veloJy::--:cl  1n  thsj_r  0\\'1!  cnte::~pTJse.  It 
must  ·be  eYJH::ct.ed  -~J..-Jat  this  2-.-~~ti·::;vJt.e  tov;o.rc.l.f~  coopero.tio~tl \·iill 
change,  too. -48-
Furthermore,  the  requirements  as to production have  increased. 
G.M.P.  (good manufacturing practice)  places  a  number  of restrict-
ions  on  the enterprises with regard  to hygiene,  control,  air 
condition,  etc.  which of course  add to the costs.  These  costs 
may  probably be  reduced  through  a  cooperation between several 
enterprises. 
During the sixties, all large Danish enterprises have  received 
offers of letting themselves be  bought up.  They  have not,  how-
ever,  wanted to  come  under foreign influence,  and  as mentioned 
the profits of the Danish enterprises have  been fairly good. 
In  a  future  situation with smaller prof.its,  such offers of 
buying vTill be more  tempting for the  ovmers. 
All things· considered,  the  future will probably see  an increased 
concentration partly due  to fusions,  partly due  to sales to 
foreign countries and partly due  to  a  closer cooperation.  Thus, 
it must  be  assumed that 'v'Ti thin 10  years there 'vill hardly be 
more  than  3  or 4  large Danish pharmaceutical producers left. 
Apart  from  the  large enterprises there are at the moment  about 
20  small ones.  This  structure may  seem surprising considering 
the  above  comments.  The  reasons vrhy  these relatively many  small 
enterprises have  been able  to hold out are: 
(l)  The  have  no  research as  such. 
(2)  They  have  specialized to  a  wide  extent. 
(3)  They have  been able to  survive because  tbey have  produced 
some  old products v1hich  are still demanded  to  some  extent,  but 
\'lhich requires  so  much  time  for readjustment,  that the  large 
enterprises have  eliminated them  from  their assortments. 
(4)  The  small enterprises have  a  greater flexibility in their 
production  (they can produce  short series). 
In spite of these  circu...rnstances,  it must  be  expected that the 
number of sma.ll  enterprises \·rill be  somevrhat  J:>e<luced!"  and  a 
certain  replacemen.t  must  be  expect  eo_. - 49-
The  Production of the Pharmacies 
The  pharmacies'  share of the total turnover of the Danish mar-
ket constitutes about  25  per cent.  This  share has been slight-
ly falling during recent years.  The  rest,  75  percent,  is equal-
ly distributed among  the Danish producers  and  importers,  the 
situation being,  however,  that the  Danish industry is losing 
ground in favour of the importers. 
The  pharmacies have  agreed to centralize the production of their 
drugs,  as the Danish Pharmaceutical Chemists'  Association has 
concluded  an  agreement  "VIi th a  number of pharmaceutical chemists 
about manufacturing and  control of certain drugs.  Apart  from 
direct sales to the public,  the  producing pharmacies in que-
stion are obliged to  supply these articles to  the  stage of di-
stribution only,  indicated by the Association. 
It muot  be  assumed that the pharmacies whjch  do  not carry out 
any actual research or development will keep  a  market  share 
of  20  per cent as  a  consequence  of the centralization process. 
It is intended to further centralize the production of the  phar-
macies,  so  that,  in reality,  the main part \'!ill be  manufactured 
in 10 large pharmacies  v:hich  in reality \'!.ill  be  cone  small 
factories.  A  few  preparations v1ith  a  large water content \vill 
still be  ma.nufacturec1  in the  i.ndi  vidual pharmacies. 
The  increased centralization has1  of course 9  posed  some  problems 
as  to  distribution.  To  solve  these  problems!:  the  Danish Pharma-
ceutical Chemists'  Association bought  two  thirds of the  share 
capital in  the whole  sale  company  Bang  og  Tegner in 1972,  and 
in October 1972  the Association concluded an  agreement v:ith 
this firm about  the  distribution. of bulk galenics,  i.e.  drug8 
or semi-manufactured drugs  in unbroken  packages  intended for 
deli  very from  the  producing pba:cmacies  to  the  purchasing  phar7,1a-
cies. 
The  distribution of the  firot preparations for  the  concentrated 
production  system started. on  lGt NoYcmber  19'~2. -50-
4.  A Qualitative Description of the Danish Drug Industry 
4.1.  Main  Structure 
!n schematic  form  figure  4.1.  shows  the  structure of the  Danish 
pharmaceutical sector,  including the position of the Danish 
drug industry. 
1.  Production of Drugs 
In Denmark  drugs  are manufactured partly by pharmaceutical fact-
ories,  partly by pharmacies.  As  a  rule,  those  drugs manufact-
ured by factories  are specialities which  are  subject to registra-
tion wlth the  Speciality Register of the  Danish National Health 
Service in order to be  sold,  whether they have  been manufactured 
in Denmark  or abroad.  Before registratioil with the Speciality 
Register the information  on  a  drug supplied by the manufacturer 
is tested by  the  Speciality Board of the National Health Ser-
vice. 
The  D~~ish Pharmacies  Act  stipulates a  number of perequisites 
for registration.  These  perequisites and  the  severe  test of the 
product for which registration is applied,  have  had  the  effect 
that the number of Danish  drug specialities,  about  1300  at the 
moment,  is low compared  to  other countries. 
According to  the  Danish Pharmacies  Act  the  pharmacies have  per-
mission tomanufacture  drugs.  Those  drugs  manufactured by phar-
macies  are not  subject to registration,  but  they must  satisfy 
requirements  as  to purity,  etc.  These  requirements are listed 
in the  pharmacopoeia and  other official collections of formulas. 
Drugs manufactured by pharmacies  may  be  divided.  into  3  main 
groups: 
~1)  Standard preparations manufactured  according to prescriptions 
accessible  to  the  public at pharmacies  or controlled laborato-
ries,  but  packed at the  dispensing pharmacy  .. 
( 2)  Inc1i  vicl.ually  corc.pounc1ed  p:reparatio~  &  ma:n.u.factured  for the 
individual patient according  to  the  prescription~ -51-
(3)  'Simple'  drugs,  i.e. preparations consisting of uncompound-
ed drugs  and  substances,  where  the manufacturing process at the 
plla.rmacy consists mainly in \veigh:ing,  etc. 
The  Danish Pharmaceutical Chemists' Association runs  a  special 
laboratory  (the  DAK  laboratory)  for development  and  control of 
and information about  drugs  and  other goods  m~~ufactured by 
pharmacies. 
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Drug  specialities are distributed to the retail outlet  (the 
pharmacies)  by wholesalers.  The  Danish Pharmacies  Act  does not 
require any authorization for this distribution activity,  but 
the existing firms  are authorized as  controlled \'rholesale  com-
panies.  The  Pharmacies  Act  does not contain any provisions for 
that matter as to authorization and control of wholesale  com-
panies.  The  pharmacies  deal mutually in their own  goods. 
3.  Retailing 
As  a  main  rule the retailing of drugs is restricted to the phar-
macies,  this restriction being part of the public  control with 
the dispensing,  storage,  etc.  of drugs.  The  Danish Ninistry of 
Home  Affairs stipulates which  drugs  may  be  offered for sale, 
dealt in and  dispensed completely or partly outside the  phar-
macies. 
The  lay-out  and  running of the pharmacies  is subject  to  a  tho-
rough public  re~tlation and  supervision. 
The  sales prices of the  pharmacies  are  fixed  by the  Government 
to  ensure  among  other things uniform prices of drugs all over 
the  country. 
4~ Hospital Dispensaries 
There  are  11  hospi  t&.l  dispensaries '\'lith  a  total turnover  ( exclu-
sive of V.A.T.)  of approx.  70  to  80  million Dkr.  This  corresponds 
to  a  little more  than half the  drug  consuiliption  of the hospitalsr 
the other half being supplied by the  pharmacies~ The  hospital 
dispensaries  may  supply only the  pat.ients  ana_  personnel of the 
hospital  service with drugs,  but  sick quarters,  camps  and  depots 
of the  armed  forces,  some  mental hospitals  and  other drug con-
suming institutions arc also  supplied  from  a  hospital dispensary. 
5.  The  JJar~.i..sh  Governrn2nte.l  Ser1Jm  Institute and  the Danish  Govern-
In  re~lity the  two  above  mentioned institutes have  a  kind  of 
Dl_O!lopoly  of mo.nufac t·u.rlHg  anc.1  d.i. spensing  seru.m  and  vaccines  o -53-
Serum,  vaccines and  other bacteriological preparations are not 
subject to registration as  drug specialities before they are 
sold. 
6.  Public  Control 
The  National Health Service is - with recourse to  the Danish 
Ministry of Home  Affairs  - the  supreme  control authority within 
the  field of drugs. 
The  speciality factories,  the  controlled laboratories  and  the 
wholesale  companies,  the  importers of pharmaceutical speciali-
ties and  pharmacies,  hospital dispensaries  and  chemists'  shops 
are inspected. 
Advertising of drugs is authorized  ~~d controlled by the Natio-
nal Health Service,  which also receives notification of the 
speciality prices of the  factories.  The  prices charged by phar-
macies  for those  drugs manufactured by  them are  fixed  on  the 
basis of calculations made  by  the National Health Service,  which 
also registrates the pharmaceutical specialities. 
1·  Prices of Dru&s 
The  consumer prices of drugs  are fixed  by the  drug scale  of 
charges which is confirmed by  Royal decree. 
The  consumer prices of drugs manufactured by pharmacies is the 
sum  of the prices fixed  by t:he  scale of the  goods  employed.  It 
is calculated by the National Health Service  on  the basi.s of 
the purchase prices paid by the  pharmacies,  to  which is added 
a  '\'IOrk  compensation fixed  by the  Goverlli!lent,  among  other things,. 
The  price of pharmaceutical specialities is notified by  the 
facto:r.·y  to the National Health Service.  The  notified price is 
tbe purchase  price paid by the  pharmacy.  To  this is adcied  the 
profit fixed by the  scale.  Thus,  there is no  control of the 
prices. 
The  pr:i..ce  \'ihicb  the  consumers  have  to  pay  for' a  clrug  depends 
on  \'Jhethcr the  drv.g in  qt:cstio~1 is subsidized  or not.  The  gre..nt-
ing of s1fbsidies  isdetermin.ed  t1y  ·che  !'j_nister :tor Soc1al Affaire 
on  recomr:1enclation  by the :L;ational Health  Serv·ice  and  the  C8mni ttee 
on  D~1gs. A new  system of subsidies was  introduced in April 1973r -54-
8.  Advertising 
Public advertising of goods  which are effective or preventive 
against diseases are  subject to restrictions which are by far 
more  extreme  than the  requirements  of the legislation concern-
ing fair and loyal competition.  The  reason for this is that the 
people  should not be  actuated to  take medicine  v1i thout medical 
consultation,  neither should  they be  encouraged to unnecessary 
consumption of drugs  or other goods  which are intended to cure 
or prevent diseases. 
The  main rule isr  therefore,  that the  law prohibits advertising 
of any article which is effective or preventive against diseas-
es or symptoms  of diseases,  but that the National Health Ser-vice 
may  allow such advertising.  Advertising of drugs by means  of 
screen advertising,  advertisement boards,  etc. is prohibited. 
:Ne~1spaper advertising of drugs  must  be  approved  beforehand by 
the National Health Service.  The  Health Service  take  counsel 
'\'-Ti th a  special Advertising Board>'  v1here  the  press is also re-
presen.ted. 
As  for doctors,.,  dentists,  veterinaries and  pharmacists this 
approval  of advertisements is not required,  but  the 1Tational 
Healt1l Service may  take action against incorrGct or inadequate 
advertising~ -55-
4.2.  The  Danish Pharmaceutica.l Factories 
In 1973,  27  firms  could be  classified as pharmaceutical factor-
ies. In that year they had  an  average  of about  600  employees 
and  a  total turnover of approx.  1170 million DkT. 
Only  8  of these  27  firms  had more  than  200  employees  and  only 
4 had  a  turnover of more  than 100 million Dkr. 
The  6  largest combines  plus  one  additional  combine  whose  main 
activity is not manufacturing of drugs proper are described 
below. 
The  largest Danish pharmaceutical factories  cooperate  through 
the trade association  MEFA. 
1.  Novo  Inudstri A/S 
Production 
This  combine is the  largest in Denmark within  drug production 
with a  total turnover in 1973  of 379  million Dkr  and  2100  em-
ployees,  1800 of whom  are  employed in Denmarko  Approximately 
165 million Dkr of the turnover originate in the  sale of enzymes 
for industrial use.  The  firm is the v1orld  1 s  largest producer 
of enzymes.  About  100 million Dkr  of the  turnover of drugs  come 
from  the  sale of insulin.  Novo  is the world's  second largest 
producer of insulin and  the world's  largest exporter.  Apart  from 
this a  substantial part of the  turnover is accotm.ted  for by 
antibiotics,  and the  firm is among  the world's largest suppliers 
of V-penici1l.in.  lTovo  also  produces medical  enzy;nes,  stcToid. 
preparations etc. 
In 1973,  the  export  of  drLJ_gs  a.nd  enzymes  totalled 92  per cent 
of total sales. 
Capital 
Figure  4. 2"  sho1·1~3  the  structure of  ~! ovo  Indv_stTi  A/S.  ~~:he  s!-.arG 
capital of the  paTent  company  11c:tS  been  increased several  times, 
tLe  last time  in Ar_;rj_l  1974  to  13~;  ml111ox--_  Dkj:'.,  The  sh&:re  capi-
tal is divld.ed  bct\·;een  45  mi1J ion  Dlcr  in A-sho.x·es  and  9C  million -56-
Dkr in B-shares.  1.000 Dkr of A-shares give  10  votes while 1.000 
Dkr of B-shares give  only one  vote.  The  ratio between  the  two 
classes of shares must not bG  upset.  The  B-shares are negotiable 
papers. 
All A-shares are  owned  by Novo's  Fund  - a  proprietary institu-
tion established by the  founders  of the  company  in 1951.  Accord-
ing to the regulations a  majority of the members  of the board 
of the  fund must not be  shareholders in the parent company. -57-
Figure  4.2.  The  Novo  Combine 
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Novo  Terapeutisk Labora-
torium A/S 
Share capital: 
40  million Dkr 
Novo  Industrie Phar-
maceutique  Paris  and 
Chartres  - Founded  1959 
Share Capital: 
FF  2  million 
Novo  Industries  (Phar- Novo  Industrie G.m.b.H. 
maceuticals)  (Pty.)  Ltd.  Mainz  -Founded 1958 
Johannesburg - Founded 
1959. 
Share capital: 
.Rand  s,ooo 
Sales  companies  Aldepha A.G. 
Zurich  - Acquired  1969 
Share capital: 
Sfr 50,000 
Novo  Espana s.A. 
l1adrid  - Founded  1974 
Share  capital: 
Ptas  5 million 
Novo  .Enzyme  Corporation 
Hamroneck,  l\f. Y  ..  ~  USA 
Founded  1969 
Share  capital: 
us  $ 1oo,ooo 
Original capital: 
Dmark  900.000 
I 
Novo  Industri  AB 
Malm~ - Founded  1972 
Share  capital: 
Skr  50,000 
Novo  Industri A/S 
Oslo  - Founded  1965 
Share  capital: 
Nkr 10,000 
H  ovo  .. Industr1  Oy 
Helsinki  - Founded  1972 
Share  cs:pita.l  ~ -58-
Sales  companies  Hovo  Industri  GmbH 
(continued)  Vienna 
Information 
offices 
Founded  1974 
Share  capital 0.  Sh.  100,000 
N.V.  Novo  Industri  S.A. 
Brussels 
Founded.  1967 
V!etenschappeli jke Dienst Nederland 
Amsterdam 
Founded  1963 
Companies  are being  estc.'blisheCl.  in Belgium. -59-
The  firm has initiated an extensive investment programme,  in-
cluding among  other things the building of a  new  insulin fact-
ory.  In the next  5-year-period the budget includes investments 
in plants of about  300  million Dkr.  The  activity abroad is re-
stricted mainly to  the  establishment of sales compru1ies  in va-
rious countires,  last in Austria ru1d  Belgium.  There  are plans, 
however,  to establish an  enzyme  factory in USA. 
Diversification 
Apart  from  the fact that drugs  ancl.  enzymes  are produced for in-
dustrial use there is no  diversification~ -60-
Prod.uction 
This  combine is the  second lc.rgest V!ithin the trade,  but the 
parent company is the  lar.::;est  :phariJ!aceutlcal factory proper in 
Denmar1\:.  The  company  h2.s  about  2000  employees in its service, 
j_ncluding 1100  to  1200 in the parznt company. 
Leo  Ph~rmaceutical Products Ltd.  proc1.uces  mainly antibiotics 
and  diuretics,  but analgesics,  vitamins  and  hormones  are  also 
produced. 
C  . t  .,  ap1  a_ 
~he combine has  the  follo\'ling structure: 
L0vens  Kemiske  Fabrik 
Producti.on  company 
(Leo  Pharmaceutical Products Ltd.  A/S) 
Industriparken  55r  2750  Ba.llerupo 
Founded.  1908t  conve:cted  j_nto  a.  limited company in 1962,. 
Share capital:  20  raiJ.li  on Dkr. 
L0vens  Kemiskc  Fa1)rik 
Trad.ine  company 
(JJeo  Pharmaceutical Produets  Trading Ltd.  A/S) 
(L5vrens  Chemj_sche  }'abrik Hondelsg8scllschaft  A/S) 
Founded 1951. 
Share  capital:  30 mj_llion  D1cr. 
Other Dani0h  coztpanies  ·ui thin the  combine: 
Pant1H.~:~  ..  I>l&.st  Aktieselskabt  founded.  19339  convex-ted  into  2. 
limite6_  comp&.ny  in 19G5. 
Share  capital:  5 million Dkr_ 
Corapar~i  es  a·br·oac1: - 61-
L6vens  LIDremed.el  Aktiebolag,  Ma1rnts,  founded  1966 
Share capital:  Skr 5,000 
EFA  Company  Ltd., Athens,  founded  1958 
Share capital:  Drs  550.000 
Leo  Pharmaceutical Products Belgium S.A.,  Br~ssels, 
founded  1967, 
Share capital: Bfr 3 million 
Laboratoire  Leo,  France  (S.A,),  Paris and Dreux, 
founded  1933,  converted iuto a  limited company  1960, 
Share capital:  FF  3 million 
Leo  Laboratories Limited,  Hayes,  Middlesex,  England, 
!'ounded 1960, 
Share capital: £ 300,000 
Leo  Laboratories Limited,  Dublin,  founded  1958, 
Share capital:  i  124,000 
Leo  Pharmaceutical Trading Limited,  Dublin,  founded  1973, 
Share capital:  £ 1,  000 
L0vens  kemlske  Fabriks Handelsaktieoelskab, 
Oslo 
The  main part of the  proc1ucts  are manufactured by  the  combine 
in Denmark  and  the rest in a  factory in Ireland,  which  supplies 
the  Bri  tioh marl~et,  and  by  a  factory in France  which  supplies 
the French  speaking markets.  The  other foreifJl  companies  are 
sales companies. 
The  shares  i~J.  the parent  company  are  not freely negotiable,  the 
large majority is O\·med  by  m&.YJ.ufacturer  X.  Abildgaard. 
Di  v£-~rs:i.fication 
The  basic  po.:Lnt  of view of the  firm is tha.t  the  combine  should 
producE::  drugs first and  foremost,  end,  there~ore,  the diversi-
fication is ver  ... v  limited.  The  plasticB factory is an  exception, 
and  SO  1s also partly the  yrOC.UCt:ion  of Yi tamin preparations  e -62-
3. H.  Lundbeck  OF- Co. 
Production 
This  combine  employs  a  total of about  1400 persons of whom  about 
650  are  employed by the parent  company in Copenhagen. 
The  main product lines of the finn are  psychcpharmacological 
drugs,  products for local combating of infections and  cancer 
remedies.  Apart  from  that the  firm manufactures products within 
the product  groups analgesics  and  sulphonamides,  among  others. 
Capital 
The  combine is organized in the  \·Jay  that the  firm  B.  IJundbeck 
og  Co.  A/S,  with a  share  capital of Dkr.  35  million together 
\vi th its subsidtary company  :( efeJ.as  A/S,  vii t!.1  a  share  capital 
of Dkr  45  million,  is O\vned  by  the  Lundbeck Foundation,  found-
ed by  the  late 1'·Trs.  Grete  Lundbecl;::. 
AB  Leo,  Helsingborg,  Sweden,  with  a  share  capita.l of Skr.  30 
million is  O'W!led  by Kefalas  A/S. 
The  Danish  company  H.  Lundbeck  og  Co.  has  the  follov;lng  foreign 
subsidia~J comp~nies: 
The  Lundbeck Corporation, 
New  York. 
L.I .c.,  Lundbeck Industries ChilJ.liques, 
Paris. 
IJlmdbeck  Arzneimi ttel G.m" b.H., 
VierL.lla. 
Lundbeck  S.A., 
Brussels. 
Oy  H.  IJundbeck  &  Co.  Ab, 
Helsinki. 
Ho  Lundbeck  &  Co.  (Holland)  N. V.  ~ 
Amsterdan1. Lundbeck  AG, 
Zurich. 
AB  H.  Lundbeck & Co., 
MalmB. 
Lundbeck  G.m. b.H., 
Hamberg. 
H.  Lundbeck  &  Co.  A/S, 
Oslo. 
AB  Leo-Intressenter, 
Helsingborg. 
I1o..ndbeck  Ltd., 
Luton,  England  .. 
Diversification 
-63-
~:he  firm produces  some  perfumery,  especially skin cream,  and 
it d.istributes  a  number of products manufactured.  abroaa,  e. g. 
hair spray  and  deodorant. -64-
4.  A/S  Dumex 
Production 
Originally,  this combine  had the  aim of handling the total Danish 
export of drugs,  but the  firm never managed  to become  a  unified 
export organization,  but became  an  independent firm.  The  combine 
employs  about  500  persons in the Danish parent company. 
The  main product line are psychopharmacological drugs  and to 
a  lesser extent vitamins  and antibiotics,  but the  firm also 
offers products within most main product  groups  of drugs. 
Q§.pital 
Until 1973,  the Dumex  combine  was  owned  by  0K  (the East Asian 
Company)  - the largest trading company  in Scandinavia.  At  that 
moment,  about  1250  persons were  employed,  and  the  combine  con-
sisted of the  following companies: 
Companies  in Denmark: 
A/S  Dumex  Agro 
A/S  J)umovl. t 
A/S  Vitapharm 
Companies  abroad: 
Dum.ex  Ltd.  Bangkok,  founded  1957, 
Share capital:  Tcs  25  million 
Dumex  Sdn.  Bhd.,  Kuala Lumpur,  found.ed  1959, 
Share  capital:  H$  650~000 
Dumex  Ltd.,  Lagos,  founded  1960, 
Share capite.l:  n£ 5.000 
Dumex  Ltd.,  Accra,  founded  1965, 
Share capital:  HC  101~000 
P.T.  Dumex  Indonesia,  Jakarta,  founded  1968, 
Sh~re capital: US$ 937,000 Dumex  GmbH, 
Ham borg. 
Dumex  Ltd., 
Durban. 
OY  Dumex  AB, 
Helsinki. 
Dumex  Lakemedel  AB, 
Helsingborg. 
Dumex  SpA, 
Milano. 
A/S  Dumex, 
Oslo. 
Dumex  Pty.,  Ltd. 
l·lelbourne. 
Dumex  Ltd., 
JJondon. 
- 65-
And  \'Ti th factories in Denmark,  Thailand,  Malaysia,  Indonesia 
and Nigeria. 
In 1973,  0K  concluded_  an  agreement  \·:i th the  large Canadian  com-
bine,  Canarlian.  Development  Corporation,  about  exchange  of a  n,Jm-
ber of companies.  0K  acquired  tho  sb.are majority in a  number 
of CDC  compar1ies  -\vi thin the fields of forestry  and mining.  In 
return,  CDC's  subsi(:ia.ry  co!npan:r'J  ConneJ.lght  Lal.;oratorJes, 
a.cqui:!:"·cd  the  sha.re  ma;j ori  ty in Dum.ex  - Copcn!lagen  and  inte-
rests in a  number  of other companies,  ovn.1ec1  by  this. combine  .. 
Di  versifj_cation 
One  of'  the  Dc::rnisl~.  suhsidj_ary  compa~.ies,  A/S  D"tt:nex  Ag:r:·o,  is 
sv_p~)lier of vi  tar:ins  a:nrl  n~"l:·citiotics  to  tl:e  livestock of the - 66-
5.  A/S  Ferrosan 
Production 
The  combine Ferrosan was  founded in 1919-20,  and it now  has  a 
total of 1000  employees.  Of  these,  about  350  are  employed by  -the 
Danish parent  company. 
The  main product groups  of the  firm are vitamins,  tuberculosis 
remedies  and  psychopharmacological drugs. 
Capital 
Ferrosan is a  Da.no/Swedisht  firm,  whose  parent compru1ies  are  the 
two  sister companies  A/S  Ferrosan,  Denmark,  with  a  share capi-
tal of 8  million Dkr  and  AB  Ferrosan,  MalmB,  Sweden,  with a  shar 
capital of 3 million Skr. 
The  two  companies are  o\mers  of shares  in  each other. 
The  owners  of the  two  companies  are  descendants of the  founders 
of the  companies  - the  families  k~d.ersen a.nd  Ryne. 
The  t\'ro  parent companies  are  co-ovmers  of a  number  of sales 
companies: 
OY  Ferrosan AB,  Helsinki,  founded  1954. 
Share capital:  Fmk  600.000 
A/S  Ferrosan,  Oslo,  founded  1960. 
Share capital:  N"kr  101000. 
A/S  Norfarma,  Oslo,  founded  1967. 
Share capital:  Nkr  240,000. 
Ferrosan  International  A/S  and  AB,  Copenhagen,  founde~ 
1970.  Share  capital  D.kr.  100.000  and  S.kr.  100.000. 
Apart  from  those,  the  Danish parent  company  has  3  subsidiary 
companies: 
foun<.led  1943~  producl.ng  aerochem:Lcal  prodncts  ffi'1d 
forage  supplements. 
Share  capital:  :Dh.--r  5 million" - 67-
A/S  DANOCHEMO,  founded  1948,  producing  and  distributing 
vitamin  concentrates  f  r  pharmaceutical  use  and  feed 
supplements,  disinfectans  etc. 
Share  capital:  D.kr.  400.000. 
A/S  REMEDIA,  founded  1957,  distributing  toothpaste, 
vitamins,  cosmetics  etc.  to  Danish  wholesalers. 
Share  capital:  D.kr.  200.000. 
Diversification 
Apart  from  what  is listed under  the  Danish  subsidiary companies 
it may  be  mentioned  that  Ferrosan  is  the  largest supplier of 
disinfectants  in  Denmark,  and  that  the  firm produces  various 
enriched  foodstuffs. -68-
6.  A/S  Alfred Benzon 
Production 
A/S  Alfred Benzon is the oldest pharmaceutical factory in Den-
mark  (founded in 1919). 
The  combine has  about  800  employees,  350  of these being employed 
by the Danish parent  company. 
The  main part of the production of drugs is concerned with such 
fields as rheumatic  diseases  and metabolic disturbances.  Also 
analgesics and remedies  against ulcers  ru1d  seasickness are pro-
duced. 
About half of the  company's  turnover originates in semi-pharma-
ceutical products  such as articles for the  care of children and 
above all special kinds  of  che'~·:-ing  gum  and  troches.  As  will be 
seen,  a  high degree  of diversification. 
gapital 
The  parent company  has  a  sha.re  capital totalllng 12  million Dkr. 
The  shares are not freely negotiable,  they are  o~med by  descen-
dants of the founders,  the  fa..mi.lies  Benzon  and Thorsen. 
The  other parent company  of the  combine,  A/S  Mecobenzon,  is 
Denmevrk' s  largest '1tlho1esale  co:npany  for drugs with  a  share  of 
the market  of about  60  per  cent~ Until 1972,  half of this  fir!Il 
which  also has a  share capital of 12  million Dkr,  was  owned  by 
A/S  r•1edicinalko,  a  company  substantially influenced. by  0K  -
the  former  0\·~'1Jer  of Dumex.  Nov;  A/S  .Alfrecl Benzon  owns  the  whole 
share capital in Mecobenzon. 
Apart  from  these  t\'lo  companies,  the  following  companies  are 
affiliated with the  combine: 
In De:nmark:  Danimed  A/S 
Share capital:  Dkr  250~000 
Chr.  Fe  Petri's eftf.  I/S Abroad: 
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A/S  Alfred Benzon 
Oslo. 
Oy  Alfred Benzon  AB 
Helsinki. 
Benzons  Farmaceutiska AB 
Helsinki. 
Alfred Benzon  (U.K.)  Ltd. 
Bellington,  Cheshire,  England 
Alfxed Benzon  B.V. 
Maarsbergen 
Alfred Benzon  S.A. 
Brussels 
Alfred Benzon  GmbH 
Ham borg 
Alfred Benzon  GmbH 
Zurich 
Alfred Benzon  Ges.m.b.H. 
Vienna - 70-
7.  A/S  Grindstedvrerket 
Production 
This  company is not  a  pharmaceutical factory proper,  but on  the 
other hand,  in 1973  the  turnover of its drug production - sold 
through its subsidiary company  A/S  Syntetic - totalled about 
96 million Dkr,  which makes it one  of the large  suppliers.  Ano-
ther reason for including the  firm here is that its production 
is not based so  much  on  pharmaceutical specialities, but  on 
synthetic drugs which  form  part of the  production of other phar-
maceutical factories. 
Furthermore,,A/S Grindstedvrerket,  which  employs  about  1100  per-
sons,  has  close  connections with the Danish food  industry. 
Capital 
Together 1tri th its subsidiary A/S  Syntetic  and  the  filhls 
Da..YJ.lac  A/  S, 
Dansk  Grerings-Industri  A/S, 
I.  KrUger  A/S,  and 
M.  Aarsleff & Co.  A/S. 
A/S  G-rinclstedvmrket  i.s  a.  subsiclia.ry  company  of A/S  Danisco. 
Diversification  ·-··  ~· 
Apart  form  drugs,  the  company  produces  emulsifiers,  enzJ~es and 
stabilizers,  aromatic  substances and  essences for the  fooo.  and 
stimulants industrieso - 71-
B.  The  Connection Betveen the Danish and the  Swedish  Pharma-
ceutical Industries 
The  Danish and  the  SitTedish  pharmaceutical industries are  close-
ly connected.  Figure 4.3. is a  list of the largest  Svredish  and 
Danish pharmaceutical factories  and their relations. 
Sweden  Den mark 
Number  of 
employees 














H.  Lundbeck &  Co.  A/S  and  A:B  IJeo,  Helsing"borg~  a  subsidiary 
company  of Kefa.las  A/S,  is ov1ned  by  the  JJundbeck l"oundation. 
Ferro  sa~,. Denmark  and Ferro  san,  Sv.reden  are  sister cowpanies. 
Pha.rma.cia9  Denoark is a  subsidia.ry  company  o~  l'harl!1C.Lc:i.a,Swe-
den.  The  other JJanish  pharmaceutical  factor.i..es  have  sales 
companies  in Swecl.en  and  the  Astra Combine  has  a  sales  compa-· 




4.3.  The  Importers 
About half the  turnover of pharmaceutical specialities stems  from 
foreign producers who  sell their products either through special 
drug importers or through their  o~m sales or subsidiary companies. 
The  main part of the multinational drug producers are represent-
ed in the Danish market.  The  following large foreign companies 
have  subsidiary/sales companies in Denmark: 
Hoffman  - La  Roche  Up john 
Ciba - Geigy  Win1hrop 
Sandoz  Abbott Laboratories 
ICI  Astra 
Bristol  Pharmacia 
Ames  Company  Bayer 
Merck,  Sharp  og Dome  Hoechst 
Pfizer  Schering A/G 
Reiker  ( 31vl)  Boehringer Ingelheim 
G.D.  Searle  Connaught 
Squibb  Organon 
Furthermore,  preparations  form  the  following large foreign firms 
are sold: 
Lede:rle  Knoll 
vlyeth  Philips - Dupher 
Eli Lilly  Roussel 
Sche:r-ing  Corporation  Janssen 
Lepetit  Boots 
Bofors  Kabi 
The  establ1.shing has been  gradual1  the normal start being that 
an importer deals in the  products of the  firm,  a.11d  vrhen  the  t-ru~1-
over has  grovrn  sufficiently large,  a  sales company is  establis}~cd  .. 
In a  fevl  casea,.  small Danish  firL"is  have  been bought  and used  a.s 
sales companies.  l.'Iul ti:national  di·v.g  proclu.cers  have not invested 
in proo.uction plants in this country  (rhal:'IO.acia  bei21g  an  excep·  .. 
tion). 
The  drug importers co-operate in the  trade  organize.-tj_on HEDJ:B'. - 73-
4.4.  The  \{holesale Trade 
The  pharmaceutical articles - manufactured  goods  as well as  raw 
materials - are distributed from  the factories  or importers 
through wholesalers to the pharmacies.  Exceptions are only the 
hospital dispensaries which  are  supplied directly from factories 
or importers.  The  only function of the wholesalers is the distri-
bution proper,  they have  nothing to  do  '\'lith  the actual sales 
promotion or the  fixing of prices.  As  far as pharmaceutical 
specialities are  concerned,  the factories  and importers fix the 
prices which the pharmacies have  to pay,  and  the wholesalers are 
allowed certains discounts  on  this price.  The  wholesale  discounts 
which are dictated mainly by the producers,  amount  to  8  to 15 
per cent on  the price paid by  the pharmacies.  As  the wholesalers 
have  no  direct influence  on  the price determination,  there is 
no  actual competition on prices.  The  wholesalers  can compete, 
however,  on  terms  of delivery and  payment,  and in this connection 
the granting of long-term interest-free trade credits has  played 
an important part.  Therefore,  the  pharmacies have  incurred sub-
strultia,l trade  debts  '\'Ji th the wholesalers,  totalling as  m,..1ch  as 
125 million Dkr,  but it is uncertain who  finances  the  bulk of 
the debts,  the wholesalers  or  the  speciality suppliers.  At  the 
moment  there are  4  wholesale  firms  supplying  pharmacc~tical spe-
cialities to  the pharmacies.  These  4  firms  are: 
(1)  Hecobenzon A/S  (Subsicliary  company  of the  pharmaceutical 
factory Alfred Benzon) 
(2)  Nordisk Droge  og  Kemikalie-Forretning 
(3)  K.V.  Tjellesen 
(4'  A/S  Max  Jenne 
On  1st April 1974,  a  fifth v1holesaler closed  do"Vm"  The  pharmacy-
Ovlned  wholes2.le  firm Bang  og  Teg-.n.er  distributes the  product.ion 
of  th~ pharmacies. 
:f\1ecobenzon  is by  :far the  largest of the vrholesalers  dealing in 
specialities v.ri th a  sha;.oe  of the mc:.rket  of about  60  per cent<# 
Norcl1sk  D:rogP.  og  Kem1ka11e-Forrctn.i.ng is the  only  o~1G  of the 
other three  of  c.ny  su.bstential :i.:nportance  !' - 74-
In the present situation,  each of the four wholesalers  can  supply 
all articles from  the importers  and  the  domestic  producers.  Re-
cent years have  seen  some  misgj_vings  as  to this system of di-
stribution,  however.  Attempts have  been made  to establish a 
one-channel distribution,  so  that an importer or a  pharmaceuti-
cal factory could supply their products  through a  wholesaler, 
and  direct distribution,  so  that the various suppliers could 
supply directly to the pharmacies of the  country through a  com-
mon  distribution centre. 
These  attempts have failed,  however,  partly because of the Danish 
Monopolies Authorities,  and  therefore  the original system is 
still in existence. - 75-
4.5.  The  Pharmacies 
As  mentioned earlier the retailing of drugs is restricted almost 
exclusively to the pharmacies.  According to  law,  the  pharmacies 
are obliged to  follo\·1  the prescriptions of the  doctors exactly, 
so  that a  pharmacy product cannot be  substituted for an  approved 
speciality.  As  a  consequence  of this obligatlon,  the pharmacies 
cannot decide  themselves  ~rhich specialities to  deal in,  but  they 
must  be in a  position to  deliver any  speciality on  the market. 
They  must  be  able  to procure  with the shortest notice possible, 
what  they  do  not have in stock. 
As  has  appeared,  the pharmacies  are monopolists within the  pro-
duct line in· question,  as  they have  a  monopoly  of dispensing 
pharmaceutical preparations according to prescriptions.  They 
also have  a  monopoly  of manufacturing drugs  that cannot be  re---
gistered as specialities according to provisions at present in 
force. 
As  per 31st December  1973,  the  348  pharmacies in the  country 
had  6.  793  employees,  of whom  789  were  pharmacists  ana.  1167 
chemist's assistants. It is those  two  groups  of personnel who 
are in charge  of the production of the pharmacies. - 76-
5.  Analyses  of Product !!!arkets 
5.1.  The  General Competitive  Situation for Pharmaceutical Pre-
parations 
5.1.1.  The  Product  Development 
Very  schematically the pharmaceutical trade may  be  characteriz-
ed as  an oligo-political trade where  the  development  of new 
products  and  the  information  and  advertising efforts are  the 
predominant means  of competitions 
In the post-war period the most  salient feature  of the policy 
of the  drug producers have  been  an  extensive  launching of new 
products.  This  product policy has  implied  that it has  been nece-
ssary to  increase the costs of information and advertising in 
connection with the  launching.  At  the  same  time it has  created 
a  radically changed  situation on  the market,  as  the  individual 
enterprise for a  certain time  obtains relatively well-protected 
market  positions for its new  products.  The  predominant  competi-
tion of earlier days  vri th considerable  price competition  on  the 
market  with standardized products is now  unusual in the  pharma-
ceutical field  ( cf.,  hO'\flever,  the market  for contraceptive pills). 
A high rate of renewal of products  and_  the  conseqv.ent  product 
differentiation implies  a  protection of the market  positions 
of the  establishecl enterprises through difficulties of establish-
ing on  the  level of both production as marketing.  It now  requiree 
relatively large financial  resources  to  establish new  enter-
prises in the  trade  of an  orcler which will influence the  compe-
titive situation.  The  vigorously increased costs which  are  neces-
sary far the  development  and  introduction of new  preparations 
on  the  Dlarket  arc  of decisive  importance  here. 
The  pharmaceutical market  is compounded  by  a  large  number  of 
more  or less d1nsti:nctively delimited  produc:t  markets.  Of  couTse, 
thecle limitation Js  concer-ned  v:i.th  fields  of a-:)plication  ..  The 
flo~ of product  innovations  during the  post-war neriod has  nad 
th~ result  that  the  nu~ber of markets  have  been vigorously in-
CT'c::.tG t=-::d  Vi11 i le  tt:_e  di  ffe::ec:n -t j_ a ti  on  -t'E'~~v:e eL  unj fo:rm  nre11:::~.rati  OY'1S 
has  nate  the  market  situn~lon difficult to  survey. - 77-
For the enterprises the splitting of the markets  means  a  protect-
ion against price  com-petition~  In many  cases,  the differentia-
tion gives the  individual nreparations  'its O\m  market' ,  "1here 
the comuetition  from  other pre-parations is negligible.  Like  in 
other trades,  the line between  product  differentiation within 
a  ~roduct market  and  the  division in more  product  markets is 
often difficult to  draw. 
At  the  same  time  the  research and  development  efforts  alv1ays 
imply  a  threat,  however,  to  the market  positions of the exist-
ing preparations.  In trades of this type it may  be  expected 
that the  individual  ~reduct at a  given  time  have yery large 
market  shares,  but that the market  shares are  subjected very 
easily to vigprous  shifts.  This will also appear  from  the  follow-
ing analyses of product markets. 
The  average  J ife-time of drugs  is 10  years.  ~,his fast rate of 
rene·\tlal  doeo  not necessarily mean,  however,  that the  market 
~ositions of the  enterprises are  insecure,  i.e.  that the  poten-
tial competition  from  other pharmaceutical enterprises is great 
on  the  individual markets.  The  obstacles to  establishing may 
often be  considerable also  on  the market  level,  so  that shifts 
between the ratio of market  shares of the  preparations mai:n.ly 
occur among  the  already predoninant  enterprises.  This  i3 partly 
due  to  the  fact  that  the  pharmaceutical field  constitutes a 
very larg,e  resep_rch  field,  and  that  the  individual enterprises 
as  a  consequence of this have  chosen  to  concentrate their largest 
research projects  on  a  small  number  of partj_al  fields.  Thus, 
the  number  of potential competitors  raay  be  relatively limited. 
5.1.2.  The  Comnetition Activities 
The  competiti.on  on  the  pharlt1aceutica1 markets  may  be  said t8 
take  place  on  two  levels: 
( 1)  The  COJP.IJeti tion bet\·Jeen  existin.; preparations takes  0lnce 
by means  of prices  and advertising.  To  a  certain extent,  the 
conditions  for  such  a  competi.tion. in tbe  indi  v~:_dua.l  product 
ma:r·kets  m~J.'t  oe  ill1Jstr~.tccJ  b~t  ~:5truct:nx·e  data  suci1  a.s  mar~~et 
c:f.  for :instance  the  r11arke t  for  t:t·e.:1q1J_ilizers.  T·:onopo~.L:\r  e,nd - 78-
strongly concentrated oligopoly situations will be  registered. 
As  a  rule the relative market  positions are  locked in the  short 
run  and  attempts  to  obtain substantial changes  trough active 
price competition or advertising cam-paigns  are unusual. 
(2)  The  most  important  and  most  resource requiring competition, 
however,  takes place in connection with the  launching of new 
products.  The  means  of competition here  assume  the  character 
of investments.  They  are research and  development  efforts and 
often a  very large use  of resources  in connection with infor-
mation  and  advertising at the  launching.  The  conditions for 
thls competition cannot,  of course,  be  illustrated by market 
shares or the  li~e,  which  are  only a  later registration of the 
results of the efforts of the enterprise.  Important  indicators 
are probably the  research resources  of the  enterprises in the 
product field in question,  the  situation as  to patents  and  the 
sales resources  ~iliich the  enterprises possess.  These  indicators 
are almost  impossible to  quantify,  hov:ever. 
Somewhat  simplified,  there are  three kinds  of launching of 
new  preparations: 
(1)  Nev.r  drpr:~ 'V!hich  are clearly superior to  the  exis-ting alter-
natives by certain forms  of treatments.  This means  that  such 
a  preparation establishes  a  ne1-1  product  market  ox·  soon  may  Gain 
a  predominant position on  an existing market.  J~xamples are  con-
traceptive pills an<l  psychopharmacological  drugs. 
( 2)  So-called  'me-_too'  -oren_~T.2·tig_Yl§. ·which  show  sn1all  di  vergen-
ces  from  the preparations already in the  product  market  in que-
stion.  The  supply of such  preparations partly through the  aeve-
lopment  efforts of the  established suppliers,  partly through 
new  establishments,  results in a  high  degree  of product diffe-
rentiation on  many  prod"J.ct  JTta:rkets.  To  a  wide  cstent the  c1e·vc-
101)ment  efforts are  done  b.Y  the  enterprises v1hich  already hav::. 
a  strone position in the  nroduct  market  in question.  ~heir 
laun.c11i:nf{',  then,  may  be  seen as  an  important effect of the  com-
petition  tct~een the  few  which  charac~erizes the  majo~ity of 
t}le  product  ma.x·kets ..  Often  the  large  enterprisE~s launch  8,  con·· 
sidcrable  21~.::_.:1oer  o:f  :cela:~i vel7  ur.:L foT'T:J.  prep~r.'l.t.:!.ons  on  'their' 
Y!lar:iccts  sin-c.ltan  CO"clsly·.  Thu::3,  Lund.  bee~:-:  for  insta.::1c e  of:'e:r's  10 
preparations  o~ the  market  for psychopharmacolofical  dJ~gs. - 79-
( 3)  S~lnonvmous pre1Jarations,  i.e. products  v1hich  as to appli-
cation are considered completely or almost  completely exchange-
able with  some  existing preparations.  Establishing of such  a 
preparation is possible if the  enterprise has  found  a  ne\'1  pro-
duction process for instance,  thus  obtaining a  patent of pro-
cess.  As  a  rule,  however,  this involves  product  fields \'!here 
the patent has  expired or \'There  the existing preparatior1s have 
not been able  to obtain the protection secured by  a  patent. 
A condition for  a  successful launching is here that the  seller~ 
can convince  the  decis1on-makers that the preparation is actual-
ly as  good  as  the  products  of the  competitors.  In contrast to 
the  'me-too'  preparati.ons,  the  price competition can be  assum-
ed  to play  a..."Yl  im-portar:tt  part at the launching.  Synor..ymous  pre-
parations are· found  for instance  on  the markets  for antibiotics 
and  psychopharmacological drugs. 
Statistical structure data are difficult to interpret.  'fhey pre-
sent  a  snapshot,  so  to  speak,  of a  space  of time,  where  changes 
are  rapid beacuse of the  product  innovations.  The  structural 
picture obtained by tabulating one  year's market  shares reflects 
completely different phases  in a  development  and  compJetely 
different competition conditions- A  decisive difficulty of a 
, 
d:yn.am5_c  description of the  competition and  the structural de-
velopment  in the individual product markets is lacking informa-
tion about  the use  of resources  for research and  development 
and  about  aovertising and  information in the  individual product 
markets. 
An  important  aspect  of the  con1peti ti  ve  situation in  thl~  J)anish 
m.arl~et  is the  relationship "betv1een  drurs !Tla..nufa.ctured  by  the 
pharmacies  an.d  p""larrna.ceutice.l  specia1i  ties including  regir~t:Ta.­
tion of  phar~accutical specialities and  provisions  for appro-
val of individual na,i'les  :for  the:n. 
The  De.nish  Pharmacies  Act  de:;ftnes  p~1c'.r:::Jaceu.tic3.l  specialities 
as  d?:uc:s  :;--cady  for  ~.,so  so1d  in  pacl~ar;cs made  by  the  IG.OJ1ufacturer 
e:nd  i:ntc:nded  for  the user  1-'_!.H~.r::;r  a.n  ind5.-v-iclual  nc:u118  or  ur~t1e:c  a -80-
The  drugs,  however,  manufactured  by the  pharmacies  are  excepted 
from the provisions  fo~ specialities and  so  are the  serum, 
vaccines,  and  other bacteriological preparations manufactured 
by the  Governmental  Serum  Institutes. 
The  relatively severe requirements v;hich must  be  satisfied be-
fore  a  preparation can  be  registered as  a  pharmaceutical speciali-
ty have had  the  effect that the  number  of pharmaceutical specia-
lities is relative modest.  At  the moment  about  1300  pharmaceut-
ical  s~ecialities are registered. 
According to a  proposal  for a  nev-1  act  on  drugs  which is to be 
read in the  Danish  'Folketing'  duringautumn  1974,  a  large part 
of the preparations manufactured by  the  pharmacies is also to 
be  registered as pharmaceutical specialities.  At  the  same  time, 
the perequisites for registration will be  eased,  so  that  an  in-
crease in the  number  of specialities of 700  to 100 is to be 
expected. 
The  pereqisi  te for registration "tlhich  v1ill  be  abolished if the 
Bill is passed is a  pereqlsi  te v.rhich  is not  found  in other coun-
tries. It is a  demonstration of a  desire to maintain a  price 
ree;ulating competition bet\'Teen  tbe  pharmaceutical industry  and 
the producing pharmacies.  In short, it says that the effective 
substa.llce  in a  clrug  must  not be  a.  common  corn.modi ty.  If i.t is 
such  a  com1110di ty its appearance must  be  due  to  a  therapeutically 
important  dj_scovery made  by the  applica_nt  or the  production 
must  require  a  special technif]_ue.  ~!he  pcre0usi  te has had  the 
effect that the  pharmacies  have  obtained  ru1  actual monopoly 
for  a  number of products,  e.g.  \'li  thin the  field of analgesics 
(cf.  section 5.5.) 
In connecti.on vii th the  registering of specialities their names 
are also  cons:Ldered.  The  provision in the  Act  nov1  in force  about 
names  is uniq_ue  among  the provisions  of other count:r-iesr  and 
it is also based  on  the  c1.esire  to  safeguard  the  p:rocl.uction  of 
the  :pharmacies  a;;ainEt  unfavoura1;1e  ccndi  tions vith ref'eren.ce 
to  a  price :regulating effect,  ainong  other things.  It is also 
a  dc::Jon.stration  of a  fecn:'  tl1at  free  accens  to ·indi  .... -.rid.ual  n2.'11en 
v:oT.tld  b:.:·ing  a  large  !1Ul!losr  of unifcn:m  proc11J.cts  on  the  market - 18-
According to  the provision  (section 74  of the  Act),  the main 
rule is that specialities must  be  registered under a  common 
name.  The  permission to use individual names  requires tbat  the 
manufacturer can  docu:nent  that he  has  performed  an  especially 
valuable effort in the  supply of drugs  to  the  population.  The 
provision is practised in the way  that the  permission to use 
the individual name  is granted to  the  inventor and to  the :Dan-
ish enterprise which  first launches  the preparation on  the  Dan-
ish market.  As  a  main rule,  the  drugs  manufactured by  the  phar-ma-
cies are  sold under  co1nmon  r.·ames. 
It is to be  assumed  that this provision has  limited the numl)cr 
of spec1alities offered for sale,  especially those  produced 
abroad,  a..""ld  therefore,  it has  influenced the  concentration in 
the individual product markets.  With  such  a  provision,  some 
enterprises may  have  desisted  from  marketing a  product  in Den-
marl(  under  a  corrunon  na::r.e,  \·ihen  they can market  the product uncler 
its indi  vid1)_al  name  in. all other countries.  The  provision about 
names  is also  giving the  pharmacies  a  preferential position, 
as  the  prescription only stating the  common  name  may  ana  probab-
ly ,,,r)_ll  be  at·~ended to  ·v;:_ th preparations manufc;_ctured  by  the 
phormacie!?· 
It is too  early to  e;i ve  a:n  estimate of what  the  provision. abcut 
ncnnes  v1ill  contain under the  ne\·l  Drugs  Act,  as thls is the most 
i!Tportant  sub;ject. of controversy.  This is of course  due  to  the 
fact  that it involves  large  commercial interests,  a,lso  vti th 
respect  to  advertis11lt:;.  There  ca::1  hardly be  a.11y  doubt  either 
that  a.lmost  ccny  change  in the provision  n.oout  na:nes  v1i.ll  imp:Ly 
a  char·,_ge  in  t~e competi-Gi  ve  situation bct\·Jeen  the  three  partj_es 
on  tbe  "'lB>rket:  the  pharn:acies,  the  domestic  producers,.  and.  the 
foreign  proclucers. - 82-
5.2.  Analyses  of Product Markets 
The  follov:ing  section includes  8  analyses  of product markets 
'vhich  may  be  divided into  3  groups: 




(2)  Vi  t&llins 
Contraceptive pills 
(3)  Insulin 
Sul  phonarni des 
Group  l  are the largest product markets  on  the Danish market 
for pharmaceutical preparations.  It must  be noted,  however, 
that the  group  tranquilizers is part of the  group  psychopharma-
cological drugs. 
Group  2  are  those  product  groups  which deviate most  from  the 
general  compet.i ti  ve  pattern 'Hi thin pharmaceutical prepa:-r:-ations. 
These  are partly standard products,  ancl  the  consumers  decide 
to  a  v1ide  extent "Vlhich  preparations are  to be  bought. 
Group  3  constitute  2  interesting product markets.  The  insulin 
market  is the most  concentrated market  \•Ti thin  the  ph.armaceutical 
market  and  the  market  for sulph8namides  :is  a  relatively new  and 
vieorously  gro1·ring  product. 
The  delimitation of the  individual product markets  follows  the 
lines  employerl  by the  two  trade  oJ_-.ganizations  l·ffiFA  and  HEDIF 
in their common  trade statistics. 
It must  be  emphasized  t!:1at  the  turnover of pharmaceutical  spc~­
cia1ities and  preparations manufactured  by  the  pharmacies is 
considere(l  and  of that  ae;ain  only what  Js  sold  thrtn,_gh  pharma-
cies  and.  other retailers for human  consumption.  Thus,  bulk  pro-
ducts  are not  included.  J~urtherr:1orc,  it nlu.st  be  c~nphasized that 
the  analyses state  purche:1.se  prices paid by the  phe.r;nacies  ..  If 
the  turnover  o:f  the  pharr~1acies stated  in selling price3 is 
,.!~;;.!.!_ted_,  the :profit nc;.r,_-;;in  of  t~_lG  pb2.I'm8.cies  :nust  be  added. 
:;;'(?:':·  t~1e  tu:r·:r--:over  of spc:.cialitie2  rnanu::Cactured  by  the  ente:r-
prises which  a.rc  :nembers  of' I,IEl'A,  the  profit margin  a:rncuntcd 
to  an  ave~age cf 33  per cent in 1968  c:J1c1  2.~  a.ver~:..[~e  of 38  l)er 
cent in 1972. -83-
5. 3.  The  Danish 11arket  for Psycho-pharmacological DruF.s 
In this connection psychopharmacological drugs  are understood 
as  the  two  main product  groups psycholeptics  and  psychoanalep-
tics.  Psycholeptics are agian divided into  t\·lo  main  groups: 
neuroleptics  and  tranquilizers,  while  psychofu~aleptics consist 
of the  t\V'O  main  groups  antidepressi  ves  and  psycho  stimulants. 
The  largest of these  product markets  and also  the most  concen-
trated is the market  for tranquilizers,  and  among  these  especial-
ly the market  for benzodiazepinderivates.  In the  following the 
total market  for psychopharmacological  drugs will be  analysed 
first,  followed  by  an analysis of the Danish market  for tran-
quilizers. 
5. 3.11  ~ehe  Total Narket  for Psyc}].ophamacological  Dru,gq_ 
On  this market  35  enterprises offer preparations for sale. 
Apart  from  that,  the  Danish  pharmacies  tr~~sact a  modest  quan-
tity.  11  of the  suppliers are Danish producers.  In spite of the 
large number of suppliers the market  is dominated  by  a  few  enter-
prises accounting for about  70  per cent of the  turnover in 1972. 
The  four largest suppliers who  had  a  market  share  of 62  per 
cent of total turnover in 1972 are: 
Dum ex 
Hoffman  I~a-Roche 
Lund  bee}: 
Ferro  S82J.  (i,'Jyeth) 
!·1arket  share  197 2 




The  total turnover stated in purchase prices paid by  the  phar-
macies  \'taB  for the  individual years: 
56,.3  - -~··-i 
1.Curn  0 v c J." 
•  ,  •  -'"\"1 
ffil..1..l1 on  .lJ.i·:r 
1969  l97H 1971 
1
1972 
---~-·~  ~ .. ---------··· 
65~7  73,0  77,0 
1973 
76,7 
Thus,  the  psychopha:rmacological  dru.6s  consti  tu-'cJ~  the  largest 
product  nc- ... r1~et  on  the  Danisb  market.  for  O.rugs ..  Decause  of.  a 
crJaTIE;:C  5_n  the  systel.rt  of  surJsidj_es  in  1973~  t'his  yee..:.c  s~n·:  a  fal.L 
in  tur·n~)Ver- in proportion.  to  the  turn.Dve:c  in 1972. -84-
1970  1971  1972 
CR4  62  59  62 
L4  0.858  0.715  0.758 
CR8  73  70  73 
Lg  0.638  OeG13  0.664 
5.3.2.  Tranauilizers 
AE  mentioned this product market is the largest v1i thin the pro-
duct  group  psychopharmacological drugs.  The  total turnover also 





1971  1972 
34,0  37,2 
In this market  the  concentration is considerably lc\·;er than 
in the total market  for psychopharmacological drugs.  The  number 
of suppliers is 9,  but the  four  smallest  suppliers have  a  negli-
gible market  share,  so  that there arc  only  5  real suppliers. 
These  5  suppliers are: 
Dum. ex 
Hoffman  La-Roche 




fJiarket  share  1972 









9~J1e  rcJ.ati  vely  1a:rge  I1inda-i:ndex  vo.lv.es  illustrate the  great 
d1:fference  ·netv.reen  the  two  laTgest  end  the  t\'lO  smallest  supplierc. - 85-
The  most  important  Dun1ex  preparation  'Stesolid'  must  be  con-
sidered a  synonymous  preparation to Hoffman  La-Roche's  prepa-
ration  'Valium'  and  the  same  applies  to the  Dumex  preparation 
'Risolid'  and  the Hofnnan  La-Roche  preparation  'Librium•.  The 
prices of the Dumex  preparations are  about  10 per cent  lO\'Ier 
than the prices of the Hoffman  La-Roche  preparations. 
During the last year the prices of tranquilizers have  been cri-
tisized. because  they \'Tere  found  to be  too high.  This is due  to 
the  fact  that Hoffman  La-Roche  lowered their prices  on  the Bri-
tish market.  Similar price reductions are wanted  on  the Danish 
market. -86-
5.4.  The  Danish Market  For Antibiotics. 
After psychopharmacological drugs,  antibiotics are  the main 
product group with the largest turnover.  The  main  product 
group  can be  divided into broad--spectered and medium-spectered 
antibiotics,  where  the broad-spectered are  tetracyclines, 
chloramphenicol,  and broad-spectered penicillins,  and where 
the medium-spectered are  erythromycin,  streptomycin,  and  me-
dium-spectered penicillins.  The  table below  shows  the total 
turnover of antibiotics stated in purchase  prices paid  by  the 
pharmacies: 
-----·---tl_9_6_8-tll9:y6_,  .  1970  1971  1972  1973 
Total turnover  45  49  55  million Dkr  61  63 
During the period,  the  turnover has been steadily increasing 
with the exception of 1973  whicl1  saw  a  fall compared  to  1972 
of about  4 million Dkr.  This fall was  due  to  a  vigorous  p?iee 
reduction of tetracycline  of about  20  per cent. 
59 
The  number of suppliers in this product market is relatively 
large,  viz.  5  domestic  producers  and  18 importers,  but  the mar-
ket is dominated  to  a  large  extent by  a  small number of suppliers. 
Although the  number  of importerR is large,  imported prepe.rations 
accounted  for anly  one  third of the  turnover.  The  largest sup-
pliers and  their approximate  market  shares are  sho·vrn  below: 
L0vens  Kemiske  Fabrik 
Novo 
Astra 
Market  share  1972 
22  5s 
--+--19_7_o  _  ~-~97:_L_~ 
cR4  Gg  I  661  G5  l 
L 4~  ____  o_._3_6_3  G·t,51  -~-346 J -87-
5.5.  The  Danish r'iarket  for A11.algesics 
This  product is highly dominated by products manufactured  by 
the pharmacies.  This  o.ominance  is due  partly to  the  perequi-
sites for rc0istration mentioned  above,  partly to  the  fact  that 
the mild analgesics can  be  obtained \'li  thout prescription.  Thus, 
the retail monopoly  of the  pharmacies  may  often becone  decisiv-e 
in the  consumers'  choice  of brands.  The  pharmaceutical factories 
cannot register the mild analgesics as pharmaceutical specjali-
ties,  and  customers \'!ho  ask for teadache  tablets at  a  pharmacy 
will be  given boxes  of tablets manufactured  by  the  pharmacies. 
It must  be  assumed  that the  competitive situation will be  in-
fluenced  by the  expected relaxations of the perequioites of 
registration in 1974/75. 
There  are  21  suppliers of analgesics in Denmark  beside  the  phar-
macies.  Of  tbese  7  are  domestic  producers.  Total  turnover for 






1970i  1971 
49,7  52,4 
1972  1973 
57,5  59,4 
The  most  important  suppliers and  their market  shares  (per cent 
of total turnover)  in 1972  aTe  stated belo\·.r: 
The  TI3..1J.ish  Pharmacies 
Sandoz 
Alfred  Benzon 
L0ven 
_  __J_  1970  1971 
CR4  I  78  79 
L4  11.880  1.  642 
- ...  _..,_11!"~  ... --... -~  .. - ..... _.,...~----... -· 
57  per ce!lt 






5. 6.  The  Danish  l~arket for Vi ta.mins 
The  market  for vitamins differs from  the other product markets 
analysed here in that there is amore  intensive distribution. 
Apart  from  pharmacies vitamin pills are also sold by  grocers, 
supermarkets  and  druggists.  This makes it diff1cult to calculate 
the total turnover.  The  tun1over of the pharBacies  for the re-
spective years  are  stated below.  The  turnover is calculated 







1972  1973 
23,1  24,8 
It is the pharmacies  themselves first and  foremost  v.rho  sell 
vitamins  through the pharmacies,  as  they account  for  about  50 
per cent of the  turnover,  but besides there  are three fairly 
large suppliers,  viz.  Ferrosan,  Dumex  and.  Pha.rmacia.  The  latter 
tvro  enterprises did not enter the market until 1971. 
A  tentative estimate of the  turnover outside  the  ph[~:rnacies 
may  be rated at about  7  or 8  million Dl-:r  per year.  1'he  uncer-
tainty of the  figures is due  to  the  fact that the  sales of the 
coopera·ci  vc  societies and  the  largest pri  vc:.tc-o~:m.ed  chain cannot 
be  calculated.  The  largest suppliers in this market  are Ferro-
san  and  Tiansk  Droge  Import.  L0ven,  in addi  tieD.  to  thP..t,  is sole 
supplier to the  cooperative societies. 
Apa.rt  from  the  Tia.nish  phEtTI18.Cies,  there  are  a  total of 7  suppliers 
of vitamin pills for hu.ma.n  consumption.  Of  these,  Roffman  La&· 
H.oche  is the  only foreign  enterprise  '"~'i th a  negligible market 
share.  The  approxi1nate market  shares of the largest suppliers 
were  in 1972. 
The  pharmacies 
Ferro  san 
D?.....nsk  Droge 
Dum ex 
Pha.rma.cia 





The  sales of vi  t::~.nins  for veterinary usc  e..re  d.omine..ted  comnletc-· 
ly by  A/S  Vi  tap:13.rm,  a  su1.)siu.ie.r:y  com:pa~y of  TJu.mex. -89-
The  index below is calculated on  the basis of the total turn-
over of vitamins for human  consvEption  on  the  Danish market. 
1970  1971  1972 
CR4  99  91  89 
L4  2.850  0.581  0.635 
The  large values in 1970  are  due  to  the  fa.ct  that there were 
only  5  suppliers,  and  that the  Danish phar:::1acies  had  more  than 
50  per cent  of the total turnovero - 90-
5.7.  The  Danish r.'farket  for Contracentive Pllls 
7  enterprises offer contraceptive pills ror Eale  i11  Denmark. 
Of these  4  are Danish and  3  are  foreign.  One  of the  foreign 
enterprises  (1~lyeth)  sells lts products  through the Danish  enter-
prise Ferrosan.  In addition to that the Danish pharmacies manu-
facture  and  sell their  o~m product. 
The  total tun1over of contraceptive pills stated in purchase 





1971  1972 
14,9  16,0 
It must  be  assumed  that the market is about  covered  so  that 
the  turnover vTill  only  grov1  \·-ri th the price increases and  the 
nv.mber  of ,_.;omen  able to  give birth to  children. 
Contraceptive pills cllffer from  the  other pharmaceutical specia-
lities in that  the various brands  do  not differ very much,  ru1d 
that both doctors  as v.rell  as  consumers  can ascertain this fact. 
They  are,  in other words,  typical standard articles offered for 
sale in the  s8..t.u.e  quantities and  packages.  The  consequence  of 
this is tha.t  :prices are uniform.  The market  shares  of the indi-
,.idual enterprises have not been very constant  d.ur1ng  recent 
years,  hO\I'lever.  •rhis is due  to  the  appearance  of new  suppliers 
and  the introd.uction of ne\A/  brands. 
The  largest suppliers  and  their approximate market  shares in 1972 









It most  be noted that Novo  did not enter the market until 1971. 
1970  197'1  1972 
CR 11  85  80  85  ,. 
lJL!  0.  5~:1  o  ~ 1).7s  0.561 
r - 91-
5,8.  The  Danish 1·1arket  for Insulin 
Insulin is a  remedy  applied in the  treatment of diabetes. It 
is offered for sale in the  form  of a  liquid and is injected 
into the  organism to  reduce  the sugar content of the  blood. 
Also  a  number  of oral antidiabetics are used  for this purpose 
and thus  these are partly substitutes for insulin. 
There  are  two  suppliers of insulin on  the Danish market:  Novo 
and Nordisk Insulin laboratorium.  \'lhile  Novo  is the world  r s  larg-
est exporter of insulin,  the enterprise sells  aJ~ost no  insulin 
in Denmark.  Thus,  Nordisk Insulinlaboratorium has  a  regular 
monopoly  on the Danish market. 
The  total turnover of insulin on  the  Danish market for the 
various years is stated below: 
1969  1970  1971  1972  1973 
Total turnover 
million Dkr 
3  3  4  5  5 
There  are  10  suppliers on  the market  for oral  diabetics~ Of 
these  4  are Danish producers.  In 1972  the total turnover of 
these preparations was  approx.  4  million Dkr.  The  largest  sup-
pliers \·!ere  Hoechst  and  Lundbeck  \vi th market  shares  of 33  per 
cent  and  30  per cent,  respectively. - 92-
5.9.  The  Danish Narket  for Sulphonamides. 
The  number  of suppliers in this product market is 12  of ~mich 








1971  1972  1973 
4,6  6,4  11,6 
It appears that the  turnover has  gro~~ vigorously during the 
last couple  of years.  This is due  to  the  appearance  of ne\"' 
combination preparations.  This has  also  resulted,  of course, 
in a  substantial shlft bet\·leen  the ratio of market  shares  •  . 
The  increase in the  share  of Gea  has been especially great. 
The  largest suppliers  on  the market  are: 
Hoffman  La-Roche 
Gea 
Pharma.cia 
1970  1971 
rJiarket  share 197? 











TABLE  OP  SYl·ffiOLS 
n  = total number of units  (firms or units of economic  activity) making 
up the  industry. 
n*  = number of units selected: 
for each hypothesis:  2,  31  4,  8,  10,  12,  15,  20  etc. 
or constituting the  sample  analysed. 
M  = average value of the variable. 
V  = variation coefficient. 
G  = GIN!  coefficient. 
H  = Herfindahl-Hirschman  index. 
E  = entropy  index. 
CR  =  share of the  first n* units  (either 4,  8,  10,  121  15,  20  etc.  or of 
the  nample  n*  selected)  ~!1  the  total of the variable. 
L  =  Linda  index:  ~~e value  of this index is calculated according to  the 
n*  hypothesis used  (either n*  = 2,  3,  4,  8,  10,  12  etc.  or:  n* 1  n*h'  n*m). 
n·lt-h  =  number  of units corresponding to  the  ~ir.it~m value of the  L index  \o;i thin 
the  s~~ple analysed. 
n*  c  number  of units corresponding to the  minimum  value  of the L index within 
m 
the  sample  analysed. 
1~  = a.ri  thmetic  mean  of the  L  indexes  on  the basis of the hypothesis  n*  = 2  s 
to n*  ,  the  formula  thus being: 
m 
L  s  = 
n*  = 2 
n*  - 1  m - 94-
Prelimin~ry remarks 
I. The  tables are based on  t~e methodology developed by the  Commission 
of the European Communities  for quantitative studies on  concentration 
trends by industr,y (see First Report  on  Competition Policy,  Part III, 
pages 157-167- April  1972;  Second Report  on  Competition Policy,  Part 
III - pages 147-161,  April 1973). 
II. The  basic data have  been assembled on the responsibility of the institutes 
which were  asked to collect them,  as indicated in the heading of each 
table. 
III.  Given the  doc~~entation available,  the  contents of each table  conform 
by and large to the plan indicated in the explanatory notes below. 
Explnna.tQrx  n_otes  to the  table§.. 
1.  'l'able  I  shows  the trend betl'leen 19  6.8 and 19 7 3  in the total figures for 
the following three variables: 
sales 
employment 
·wage  and salary bill 
The  table concerns both the total number  of units (firms or units of 
economic actiYity) me.king  up  the  industry(n)  u.nd  a  sample  (n*). 
Here  the  sa.r11ple  comprises  the  largest firms  in the  industr.;.  Their 
number  varies according to the degree  of oligopoly in the  industry and 
aloo according to the  individual statistical sources available. 
As  regards the  three variables  (sales,  employment,  wage  and salary 
bill) the trend in the figures  relates both to the  industry total a.nd 
to  thE:~  sample. - 95-
2.  Table  2  shows  the trend of concentration for three variables - sales,  employment 
and d-;e and  salar,y bill. 
The  measures  and  indexes used in this table are  obtained from  the following 
formulae: 








v  =  vvari~  coefficient 
L.__  (xi - M)2 
i  = 1 
n 
V a  ---------------------- },{ 
0  v  (n- lJ 
G  =  Gini  coefficient 
1 
L~ 
G =  __  .........,.......__ 
n  •  x 
i  Q  1 
H  =  r~rfindnhl-Hirsch~in index 
n r:;  1000 
E  '"·'  entropy index 




i  = 1 





- 1). Fx.  - i.Fx.  l1  l.  l  -_~j 
n 
L_ 
i  = 1 
1  x.  og  l. 
0  n-
n 
1000  1000  - n 
100(-logn)  0 
The  definitions of the  fo:""inulae  are  given for simple  statistical series.  It 
is e.ssumcd,  therefore,  th.:tt  the  valu€l  of the  vrtriable  is knoHn  for each unit 




n  •  number of units in a  set (l) 
X  =  total value  of the variable  in a  set 
i  unit  i 
=  value  of the variable for unit  i 
=  accumulated value  of the variable  up  to unit  i 
3.  Table  3 is intended to show  the 'W.!!f!  since 19  6 8 in the  level of concentration 
of large firms.  It comprises three  sheets,  one  for each of the variables used, 
in the  following order: 
sales 
employment 
wage  and salar,y bill 
Each variable  is intended to highlight  a  given aspect  of the  structure of the 
sample  compriEing the  large firms  and enables  significant  comparisons to be 
made  between the  tren~s in different variables. 
He.re  the trend in the  level of large firm's concentration is measured by  Linda. 
indexes  and concentration ratios. 
The  Linda index is calculated for each variable,  while  the  concentration ratios 
relate to the first three  variables  (sales,  ernplo~ent, wage  and salary bill). 
In Table  3 the  L  index is not  calculated in respect  of the entire  industr,y (n) 
but  only for the  s~~ple (n*)  and for the various r,vpotheses 4,  8,  10,  12,  15,  20 
etc.  within the  sample. 
The  table also gives  the  maxirnl~ value  (L~) and  th~ minimum  value  (Ln;)  of the 
various  L indexesJcalculated in the  interval betrreen n*  ==  2  and  n*  =entire sample. 
The  Linda  index is defined as  follows:  n*  - 1 
) 






{1)  It r.;hould  be  remembered  that  nma.ll  a."ld  fa  .. nily  bus:i.~~~cssee have  sometimes  had  to 




i  n«·  - i  A. 
Ai  l  n*  i  EO.  ..  - 1  A  - A  1  A*- A.  - n*  i  n·  1  i  1  - Ai 
n* - i 
=  CQmulative  share  of the first  i  undertakings in the set oelected 
A * =  100%  =  1  n 
That  is to say: 
{a.)  The  L or Ln*  index is the arithmetic mean  of the  (n* - 1)  ratios of 
oligopoly ecurilibrium  (Eo),  each being divi.ded previously by E.!· 
{b)  Each  EO  ratio is expressed by the  average  size of the first i  firms  and. 
th..'l.t  of the  remaining ( n'*  -_i)  firms,  -..rhere  L  in t·u.rn,  ha.s  the  va.lu.es 1 
(e~~ressing the ratio between the  size of the  largest  firm and the  avera5c 
size of all the other firms  in the  sample  of the  industr.J~ selected) to 
n* - 1  ;  this is why the number  of EO  ratios in question is c:>:actly n!_.=.J.. 
'!'he  upp:::r  a.nd  lot':'er  limits of the  L  index are  oo  and 1  respectivelye  (1) 
n* 
The  tonnula for the  concentration ratios is the follouing: 
n* 
where~ 
CJ\t  ~  1~0 L  xi 
i  = 1 
n:t.·  a  number of 'I.Ulits  selected: 
for each hypothesis:  2,  3,  4,  a,  10~  12,  151  20  etc. 
or constituting the  ~a!uple analysed., 
'11}10  upp8r and  lower  limite of  CHn~· a.ro  100  and>  0  respectively. 
4.  Table  3 b1s is intonded to  provide  an  eJlalytical dccc:r·ipticn of tho  structu1·e  of the 
large  fh'iilS  for  t-ach  yaar under·  consia.e:ra  ... .;ion  .. 5· 
- 98-
There are in fact  sheets,  one  for each yea.r,  from  19  6 8to 19 7 3.  This enables 
significant comparisons  to be ntade  between  the  indexes calculated on  the basis 
of the different variables.  As  they relate to  the  same  period and  are based on 
the  same  hypotheses of n*,  these  indexes are homogeneous. 
It should be  stressed that the analytical description in Table  3 bis was  designed 
precisely to give a  clear picture of the structure of the  firms without revealing 
individual details. 
The  values of the L indexes are given for each of the seven variables,  and  for 
comparative purposes  the 
are also indicated. 
minimum  and  maximum 
(Ln*  ) 
__  m_  {L * ) 
n  h 
C:I:II:D 
This table,  therefore,  highlights the complete  series of Linda curves from 
n*  a  2 to n*  a  entire sample. 
Table  4  summarizes  by reference to the  L  index the trends in the various aspects  s 
of the structure of the large  firms,  constituting the  sample.  This reveals the 
trend in the  indexes bett-teen 19  6 8 and 19 7 3,  calculated simultaneously on  the basis 
of all the variables used. 
As  regards  the columns  in this table,  the  following should be noted: 
The  n«·  indicate the number  of firms  corresponding to the minimum  value of the 
m 
L index within the  sample  (n*)  selected,  while  Ln*  is the value of the relevant 
L index.  The  arithmetic mean  of the  L indexes  ~from  t 2  to Ln*  inclusive, 
m  gives  the L  index,  which  expresses  the degree of equilibrium  and of 
s 
concentration between  the first n*  firms  in the  industry.  m 
(1)  Sec  R.  IJ_nda,  Tc  systeme  rles  ir1dices  d' equj_libre  et son appli-
catior:  co-ncrete  a  la siclerurgie  des  Etatt>  1]nis,  in  11Hivista 
di  J'o1.itic2~  }~cononica,  :~1o::1a,  Fai  l9E8. 
C.  l":arfels,  A  ?evt  Lao}<:  at the  StTncture  o7.'  Cl.igopoly  ir..  "Zeit-· 
sc1::r·ift  fU:r  die  geso.m~~e  Staats,;:lsse~lschaft';  197a4,  tT .C .. B.  I.tioler 
(Paul  Siebech) s  ~2tl1;i:ngen,  :pages  2L~9/270. - 99-
The  texts of tables 1  to  4 are  in French.  The  trgnslation of 
the  individual variables is as  follows: 
Turnover= Chiffre  d'affaires 
Persons  employed  =  Effectifs 
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